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A. INTRODUCTION
Huntingtons disease (HD) is a fatal, progressive neurodegenerative disease that has long been
considered one of the most serious genetic conditions of adult life. HD exhibits a prevalence of 2.71 per
100, 000 individuals worldwide (Pringsheim et al., 2012). The genetic mutation is inherited in an
autosomal dominant manner, and symptoms generally onset in mid life (1993). HD is characterised by
the progressive loss of neuronal cells in the brain (Reiner et al., 1988). A multitude of symptoms with
varying levels of severity are observed in the HD population depending on the level of progression of
the disease, beginning with subtle motor anomalies and or cognitive defects followed by increasingly
severe and devastating motor, behavioural and mental deterioration, which ultimately leads to death in
HD patients (Ho et al., 2003, Paulsen et al., 2001b).

2. BACKGROUND, CURRENT UNDERSTANDING & SIGNIFICANCE
2.1. Epidemiology
HD affects all populations but with variable prevalence rates across different demographic locations.
The worldwide prevalence rate of HD is 2.71 per 100, 000. Europe, North America and Australia show a
particularly high prevalence rate (5.7 affected individuals per 100 000). Notably, Asia displays a low
prevalence of 0.4 per 100, 000 (Pringsheim et al., 2012).
2.2. Genetics
As HD exhibits autosomal dominant inheritance, the offspring of an affected individual have a 50% risk
of inheriting the mutation. The mutant huntingtin (Htt) gene is responsible for the manifestation of HD
(1993, Walker, 2007)). The Htt gene is located on chromosome 4p16.3, from base pair 3,076,407 to base
pair 3,245,686 (Walker, 2007). The mutant Htt gene is distinguished by an expansion in exon 1
comprising an unstable cytosine-adenine-guanine (CAG) trinucleotide repeat (Fig. 1) (Spires and
Hannan, 2005). Gene negative individuals possess alleles with 10-35 CAG repeats at this location
whereas gene positive individuals bear CAG repeats in excess of 35. People with 36 to 39 CAG repeats
demonstrate reduced penetrance and may or may not develop the signs and symptoms of HD
(Rubinsztein, 2003). Individuals with intermediate alleles, in the range of 27-35 CAG repeats, do not
themselves develop HD, however they are at risk of transmitting the disease to their children through
genetic anticipation (Ranen et al., 1995), which occurs due to the unstable nature of the CAG repeats.
As the altered Htt gene is passed from one generation to the next, the size of the CAG trinucleotide
repeat may increase in size (Ranen et al., 1995). Interestingly the risk of expansion is more frequent in
1

spermatogenesis compared with oogenesis (Pearson, 2003). HD has 100% disease penetrance in those
individuals who possess 40 or more CAG repeats (1993). When there are greater than 60 CAG repeats,
the individual develops Juvenile HD, a severe form with disease onset in childhood or adolescence
(Andrew et al., 1993). No case of HD has been diagnosed with a count less than 36 (Brinkman et al.,
1997).
A) CAT-ATT-GAG-GTA-TTA-GCC-CTA-GGT-CAG-TAC-ATC-GTA-TAG-CTA-CAT-CGA-CAG-CAG-CAG-CAG-CAGCAG-CAG-CAG-CAG-CAG-CAG-CAG-TAG-GTA-CTA-ATC-GAT-CGG-CCG-CGA-TTA-CGT-GCT-GAA-TAG-AATAGT-ACT
B) CAT-ATT-GAG-GTA-TTA-GCC-CTA-GGT-CAG-TAC-ATC-GTA-TAG-CTA-CAT-CGA-CAG-CAG-CAG-CAG-CAGCAG-CAG-CAG-CAG-CAG-CAG-CAG-CAG-CAG-CAG-CAG-CAG-CAG-CAG-CAG-CAG-CAG-CAG-CAG-CAGCAG-CAG-CAG-CAG-CAG-CAG-CAG-CAG-CAG-CAG-CAG-CAG-CAG-CAG-CAG-CAG-CAG-CAG-CAG-CAGCAG-TAG-GTA-CTA-ATC-GAT-CGG-CCG-CGA-TTA-CGT-GCT-GAA-TAG-AAT-AGT-ACT

Figure 1: A) Depiction of Exon 1 of the HTT gene in a normal individual containing less than 35 CAG repeats. B)
Depiction of Exon 1 of the HTT gene in an HD carrier, with greater than 35 CAG repeats.

The CAG length accounts for only 40-50% of the variation of age of onset, with environmental factors,
parental age at onset, paternal versus maternal transmission, additional genetic polymorphisms and
interaction between expanded CAG length and normal alleles accounting for the remaining 50-60% of
the variation (Wexler et al., 2004). A recent study conducted by Aziz and colleagues in 2009, found that
the normal Htt allele can also affect the severity of the disease (Aziz et al., 2009a). In subjects with
CAG expansions in the low range, increasing the size of the normal CAG repeat correlated with more
severe symptoms and pathology (Aziz et al., 2009a). Increased CAG repeats in the mutant Htt gene
leads to an increase in the number of glutamine residues in the encoded Huntingtin protein (HTT)
(Martin et al., 2008). Disease symptoms caused by the mutant HTT protein are widespread and are
discussed below.
2.3. Symptoms of HD
The median age of adult onset HD occurs between 35 and 50 years (Beighton and Hayden, 1981). In
approximately 10% of patients who express the juvenile variant of the disease, symptoms are evident
before the age of 20 (Conneally, 1984). HD symptoms are multi factorial in nature and encompass
progressive emotional, psychiatric, cognitive, psychological and motor dysfunction (Ho et al., 2003,
Paulsen et al., 2001b, Soliveri et al., 2002, Smith et al., 2000).
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Progressive weight loss, skeletal muscle wasting, altered sexual behaviour and sleep disturbances, in
particular changes to the sleep-wake cycle, are evident in the initial stages of the disease, and are
thought to be a result of hypothalamic dysfunction (Politis et al., 2008). This is further evidenced by a
study conducted by Wood and colleagues in 2008 who found an increase in thirst and drinking in mice
affected with HD (Wood et al., 2008). Weight loss in HD is not so much due to increased or
hyperkinetic movements but is directly correlated to CAG repeat length and is likely to result from a
basic deficit in metabolism and a hypermetabolic state (Aziz et al., 2008, Goodman et al., 2008).
Similarly, mouse models of HD with a larger CAG repeat length have a lower body weight, despite
increased caloric intake (Aziz et al., 2008).
Psychiatric problems in HD are well described and include depression, anxiety and aggression
(Craufurd et al., 2001). Depression, a common psychiatric feature of HD, is often associated with
increased suicidal ideation (Chatterjee et al., 2005). Mood fluctuations and anxiety disorders are also
typical psychiatric features of HD (Pflanz et al., 1991, Marder et al., 2000, Paulsen et al., 2001a, van
Duijn et al., 2007). Elevated levels of anxiety can also be attributed to increasing motor abnormalities
that require hospitalisation (van Duijn et al., 2007).
Dementia or gradual impairment of the mental processes which are involved in comprehension,
reasoning, judgement and memory are evident, together with deficiencies in attention, concentration,
problem solving, executive functioning, psychomotor skills, verbal fluency and working memory
deficits in HD individuals (Marder et al., 2000, Roos, 2010, Anderson and Marder, 2001, van Duijn et
al., 2007).
As the level of disease progresses, the number and severity of symptoms increases. Progressive severe
skeletal muscle atrophy is a common feature, possibly due to a hypermetabolic state as a result of
mitochondrial dysfunction (Saft et al., 2005). Eventually patients exhibit signs of chorea, gross/fine
motor skill execution impairments, as well as severe gait and balance difficulties (Cummins et al., 2011,
Paulsen et al., 2008). These defects commonly lead to falls, loss of functional independence (Roos,
2010) and nursing home placement (Wheelock et al., 2003).
Patients become increasingly dysarthric, and eventually lose the capacity for effective verbal
communication (Roos, 2010).

Musculature involved in swallowing is also affected; aspiration

pneumonia secondary to food inhalation is the predominant cause of death in HD patients (Heemskerk
and Roos, 2012).

3

2.4. Neurophysiological features of HD
Although the HTT protein is ubiquitously expressed throughout the body, CNS degeneration is the most
profound clinical feature of HD. Within the brain, the striatal neurons are most severely affected and
undergo extensive degeneration (Trottier et al., 1995). Interestingly, varying levels of degeneration are
observed within the different neurons in the striatum and it has been shown that 95% of GABAergic
medium sized spiny neurons preferentially degenerate in HD, whereas the medium aspiny cholinergic
interneurons containing somatostatin, neuropeptide Y, or nitric oxide synthase are relatively exempt
from degeneration (Vonsattel et al., 1985, DiFiglia et al., 1997). Furthermore, preferential loss of striatal
projection neurons has been observed at differing stages of HD progression. In the early and middle
stages of HD, enkephalin-containing neurons projecting to the external portion of the globus pallidus are
the most effected neurons (Zuccato et al., 2010).

At the more advanced stages of the disease,

projections to all striatal target areas are depleted, with the exception of the striatal projection to the
substantia nigra pars compacta (Reiner et al., 1988).
One hypothesis for the increased, specific loss of striatal neurons is the observed loss of BDNF in this
region. This will be described in more detail in section 3.1 of this thesis.
Although the striatum is the most profoundly affected region in the brain, studies have found that the
cerebral cortex (Rosas et al., 2008, Aylward et al., 1998), globus pallidus, thalamus, subthalamic
nucleus, substantia nigra, white matter (Bohanna et al., 2011, Reading et al., 2005) and the cerebellum
are also markedly affected (Kloppel et al., 2009). Furthermore, the hypothalamus has been found to be
significantly atrophied, and this is further evidenced by the loss of orexin, hypocretin and somatostatinpositive neurons in the lateral hypothalamus (Petersen et al., 2005, Reiner et al., 1988, Gabery et al.,
2010, Soneson et al., 2010).
2.5. HTT protein
The function of the normal HTT protein is still under investigation, however studies have reported HTT
to be fundamental in embryogenesis, early neural development, and craniofacial development. HTT has
also been shown to be of vital importance in adult life (Reiner et al., 2003).

2.5.1 HTT in early embryonic development
It has been reported that complete deletion of the Htt gene in homozygous knockout mice (Hdh-/-),
results in embryonic death between day 8.5 and day 10.5 (Duyao et al., 1995, Nasir et al., 1995, Zeitlin
et al., 1995). Several studies conclude that this is due to increased apoptosis in the embryonic ectoderm,
shortly after the onset of gastrulation (Leavitt et al., 2001, Van Raamsdonk et al., 2005). Mice
4

homozygous for the expanded CAG alleles, that do not express wild type (WT) HTT protein, develop
normally and have no apparent defects which suggests that the CAG repeat does not affect the
physiological function of HTT during prenatal development and that mutant HTT can compensate for
the loss of WT function during prenatal development (Reiner et al., 2003).

2.5.2 HTT in early neural development
HTT has been found to be critical for cortical and striatal development in mice. Late term embryos and
post partum mice with HTT below 50% of WT levels, have severe defects of the cerebral cortex and
striatum, telencephalic ventricular enlargement, and agenesis of fibre tracts (White et al., 1997). In more
severely affected mice, brain defects are accompanied by craniofacial deformities. These developmental
abnormalities tend to result in perinatal lethality. In contrast, HTT is not required for differentiation and
survival of other neurons that therefore function normally. For example HTT -/- neurons in the
hypothalamus, striatum, cerebellar granule cell layer and hindbrain develop normal morphology and
neurotransmitter content with no evident signs of brain pathology (Reiner et al., 2001).

2.5.3 HTT in adult life
Various studies have highlighted the continued significance of normal HTT function in adulthood
(Cattaneo et al., 2005, Reiner et al., 1988). They have found that HTT is essential for survival of
neurons in the cerebral cortex and striatum (Reiner et al., 1988). HTT has an anti-apoptotic function.
Moreover, HTT is required for the secretion of one of the most active members of the neurotrophin
family of growth factors, Brain Derived Neurotrophic Factor (BDNF). The importance of HTT in
relation to BDNF will be explained later in this thesis.

Studies involving immortalised striatal-derived cells overexpressing the WT HTT protein have
demonstrated that the normal HTT protein is neuroprotective in CNS cells exposed to various toxic
stimuli (Van Raamsdonk et al., 2005). Overexpression of normal HTT protein has also been shown to
protect against ischemic injury in vivo in a dosage dependant manner (Leavitt et al., 2012). In contrast,
cells are made more susceptible to ischemic injury by the mutant HTT protein (Zeron et al., 2002).

WT HTT protein has also been shown to be of importance in fast axonal trafficking (Gunawardena et
al., 2003). Moreover, it has been postulated that HTT is an essential scaffolding protein involved in
axonal transport and may have a role in initiating bidirectional trafficking (Block-Galarza et al., 1997,
Gunawardena et al., 2003). Striatal neurons derived from embryonic mice which express one copy of
the WT HTT allele have mitochondria that become progressively immobilised (Trushina et al., 2004).
5

It is important to note that the functions of WT HTT protein are still not fully understood. Insight into
the structure of the protein provides some understanding of its function and therefore of the pathophysiology of HD.

2.5.4 Structure of HTT protein
The HTT protein is a large, complex, completely soluble protein, comprised of 3,144 amino acids
(Zuccato et al., 2010). A notable feature of the HTT protein is the polyQ tract at its NH2 terminus (Fig.
2) which, in unaffected individuals, contains up to 35 glutamine residues, whereas HD patients possess
greater than 35 residues (Rubinsztein, 2003). The polyQ tract is a key regulator of the binding of HTT to
its various interactors (Tartari et al., 2008). The polyQ region is followed by a polyproline (polyP)
stretch whose function is thought to stabilise the polyQ tract by maintaining its solubility (Steffan et al.,
2004).

Figure 2: The HTT protein contains a polyglutamine tract (Q)n, followed by a polyproline stretch
(P)n and 16 HEAT repeats which are arranged into 3 groups (red boxes). The HTT protein also
contains a functionally active carboxy (C)-terminal nuclear export signal sequence. Adapted from
Cattaneo et al., 2005.

Downstream of the polyQ tract, there are 16 HEAT repeats arranged into 3 groups. HEAT sequences are
~ 40 amino acids long and are involved in protein-protein interactions (Neuwald and Hirano, 2000).
HTT contains at least 4 cleavage sites for several proteolytic enzymes, including caspases, calpain and
aspartyl protesases which cleave the protein and generate a wide range of fragments (Wellington et al.,
1998). Interestingly it has been found that cleavage by caspase 6 is particularly toxic and is a crucial
event in HD pathogenesis (Graham et al., 2006). The contribution of HTT proteolysis to cell functioning
is unclear, however in HD, proteolysis of the mutant form of HTT causes a number of gain of function
mechanisms in cells (Hermel et al., 2004) which will be explained later in this thesis.
6

The first 17 NH2 terminal amino acids of HTT form an amphipathic α-helical membrane binding
domain that is necessary and sufficient for its colocalisation with the golgi apparatus and the
endoplasmic reticulum (Atwal and Truant, 2008, Rockabrand et al., 2007).
A functionally active carboxyl C-terminal nuclear export signal (NES) sequence and a less active
nuclear localisation signal (NLS) are present in HTT, which might indicate that the protein (or a portion
of it) is involved in transporting molecules from the nucleus to the cytoplasm (Xia et al., 2003).
Removal of these amino acids causes the HTT to accumulate in the nucleus, as found in HD (Cornett et
al., 2005).
2.6. Mutant HTT

Figure 3: Representation of the various cellular pathways that are affected in the pathogenesis of
HD. (A) Mutant HTT protein is more susceptible to proteolytic cleavage at its NH 2 terminal. In the
cytoplasm, the fragments are targeted to the proteosome for degradation however the proteosome
becomes less efficient in HD. (B) The fragments containing the expanded polyQ stretch accumulate
in the cytoplasm and intereact abnormally with other proteins, (C) impair calcium signalling and
homeostasis, (D) bind directly to mitochondria and cause mitochondrial dysfunction , (E)
translocate to the nucleus and cause transcriptional dysregulation of certain species including
BDNF, or form intranuclear inclusions and (F) alters vesicular transport (Zuccato et al., 2010).
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Although there is considerable evidence that normal HTT is required for cell survival, and that a loss of
function of normal HTT protein can be involved in neurodegeneration, the expanded polyQ tract in
mutant HTT (mHTT) has also been associated with gain of function in the pathogenesis of HD (Zuccato
et al., 2010).
Mutant HTT protein fragments generated by proteolysis are targeted to the proteosome for degradation
and expulsion from the cell, however the proteosome is inhibited in HD and these fragments then form
aggregates in the nucleus of neuronal and non-neuronal cells in HD (DiFiglia et al., 1997) (Fig. 3).
Aggregates are thought to be formed from fragments which undergo post-translational modification and
subsequently misfold leading to the formation of protein aggregates which form the fibrillar structures
observed in the nucleus and cytoplasm of HD patients. These aggregates then interact abnormally with
other proteins (Fig. 3B), whereas full length normal HTT is predominantly diffuse in the cytoplasm of
brain cells (DiFiglia et al., 1995, Li et al., 1995, DiFiglia et al., 1997). This highlights the similarities
between HD and other neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease and
prion disorders (Ross, 2004). Protein aggregates are seen increasingly as the disease state progresses.
However the presence of these protein aggregates is not necessary for neuronal death to occur (Tydlacka
et al., 2008) and it is still not known if the aggregates are part of the pathogenesis of HD or an end
product of an upstream toxic event. Some studies have even suggested that aggregates are actually
neuroprotective because they stimulate the autophagic process and clearance of mHTT (Saudou et al.,
1998).
Mutant HTT proteins bind directly to mitochondria and alter their metabolic activity and motility, and
this binding increases with patient age (Fig. 3(D)) (Choo et al., 2004, Orr et al., 2008). Energy
metabolism defects and oxidative stress are observed in HD (Panov et al., 2002). Moreover, mutant
HTT causes cytosolic overload of Ca2+ by enhancing N-methyl-D-aspartate receptor (NMDAR) function
(Fig. 3(C)) (Young et al., 1988). Finally, mHTT protein alters the vesicular transport of proteins,
including BDNF (Fig. 3(F)), which will be detailed later.

2.7. Pharmacotherapies
Therapeutic targets which act upon both mutant and WT HTT protein are therefore not feasible options
in the treatment of HD as HTT is fundamental for human brain development, maturation and survival.
To date, no cure for HD exists and current pharmacological therapies act merely to alleviate the severity
of psychiatric, cognitive and motor symptoms observed in HD, and often lack long term effectiveness
(Agrawal et al., 2005). HD patients are administered a multitude of drug therapies to manage the triad of
symptoms associated with HD (Agrawal et al., 2005). Current pharmacological therapies have not been
8

designed specifically for HD patients, but rather are designed for the general management of the
symptoms observed in HD and unfortunately have a large range of undesirable side effects (Table 1)
(Bonelli and Hofmann, 2004). These drugs include dopamine depleting agents, benzodiazepines,
skeletal muscle relaxants, botulinum toxin and anticonvulsants for symptomatic relief of the motor
impairments in HD (Ross and Tabrizi, 2011). Pharmacotherapy for the alleviation of the myriad of
psychological and cognitive impairments in HD include typical neuroleptics, Selective Serotonin
Reuptake Inhibitors (SSRIs), hypnotics, anticonvulsants, atypical neuroleptics and mood stabilisers such
as lithium (Ross and Tabrizi, 2011). Pharmacological approaches to delay the age of onset and rate of
cognitive decline in HD have not been discovered to date. There is an urgent need to identify alternate
treatments capable of impacting on disease progression and improving quality of life whilst the search
for a curative treatment continues.
Table 1: A summary of the drugs commonly prescribed for HD patients for the management of their symptoms and the
multitude of side effects of these drugs (Ross and Tabrizi, 2011).

9

3. ENVIRONMENTAL ENRICHMENT
3.1 Environmental Enrichment in Huntington’s Disease
Environmental enrichment refers to specific modifications in cognitive, sensory, motor and behavioural
stimuli in addition to increased physical activity and social stimulation. Environmental enrichment has
been shown to be one approach that has proven successful in delaying the age of onset and symptom
progression of several neurodegenerative disorders including Alzheimer’s disease and Parkinson’s
disease (Young et al., 1999, Nithianantharajah and Hannan, 2006).
Various studies involving mouse models of HD have demonstrated that HD mice subjected to
environmental enrichment, exhibit delayed disease onset, improvements in motor symptoms, slower
rates of disease progression, reduced cerebral volume degeneration and a longer life expectancy. The
first study of this kind was conducted by van Dellen and colleagues (2000), who provided an enriched
environment to 30 HD mice which included cardboard, paper and plastic objects in the cages. By
contrast a non-enriched group were housed in standardised caging. This study found a statistically
significant difference in the age of onset of HD symptoms and a reduction in cerebral volume
degeneration in the enriched mice compared to the non-enriched mice. A subsequent study conducted by
Hockly and colleagues (2002) which investigated three levels of enrichment in HD mice (no
enrichment, minimal enrichment and high enrichment); Found that enriched mice displayed a significant
improvement in grip strength, in addition to a significant delay in peri-striatal cerebral volume loss. The
amelioration of cerebral volume loss in both of these studies indicates a possible neuroprotective
capacity of environmental enrichment in HD. In addition, a study conducted by Spires and colleagues
(2004) has demonstrated that BDNF deficits in HD mice were completely rescued subsequent to
environmental enrichment. BDNF is a fundamentally important neurotrophin with many functions, one
of which is the maintenance of the hippocampal, cerebro-cortical and striatal neurons. Furthermore, a
study conducted by Lazic and colleagues (2006) has demonstrated improved hippocampal neurogenesis,
survival and integration into circuitry in HD mice after environmental enrichment. Moreover,
environmental enrichment in HD mice results in significant motor and behavioural improvements
compared to mice that were kept in a non-enriched environment (Schilling et al., 2004). Finally,
longitudinal studies of the effects of environment enrichment demonstrated a longer life expectancy in
the HD environmentally enriched mice relative to the mice that were kept in standard caging (Schilling
et al., 2004).
Despite these encouraging results in transgenic mouse models of HD, very few human trials of
environmental enrichment have been implemented in HD patients. Where they have been implemented,
it has been found that it leads to increased self awareness and self esteem, and improved physical,
10

mental and social functioning, even in the latter stages of disease progression (Sullivan et al., 2001,
Wexler et al., 2004). A study conducted in 2001 by Sullivan and colleagues, in 20 mid to late stage HD
patients subjected to a 12 week enrichment program, resulted in improved physical, social and
psychological wellbeing. Increased self-worth, social interaction and greater communication and
verbalisation were also observed in these patients after treatment (Sullivan et al., 2001). A more
comprehensive study assessed the effectiveness of an environmental enrichment program on forty HD
patients (Zinzi et al., 2007). Subjects were required to perform 3 weeks of intensive rehabilitation, 3
times per year over a 2 year period with 11 of the 40 HD subjects completing all 6 admission periods.
Rehabilitative exercises included respiratory exercise, speech therapy, occupational therapy, cognitive
and physical therapy exercises. Improving motor performance was a primary aim of the study, so
physical therapy included cycling, walking, stepping, balancing, resistance training and body weight
transfer exercises. Upon completion, HD participants showed statistically significant improvements in
motor performance (p<0.001) by the Physical Performance Test and Tinetti Mobility assessment
measures. Additionally the study documented improved Zung depression scores and improved
psychological wellbeing (Zinzi et al., 2007). The largest and most comprehensive study of enrichment in
HD patients was conducted by an international, interdisciplinary team who documented the extent and
progression of the disease in a group of Venezuelan HD kindreds and noticed that prolonged
environmental modifiers play a role in modifying the age of onset in HD gene positive individuals
(Wexler et al., 2004).

Several studies in which exercise rehabilitation alone has been implemented in HD patients, have
revealed significant improvement in symptoms (Quinn and Raio, 2002, Zinzi et al., 2007, Peacock,
1987). A study in which 10 HD patients were administered a 12 week home based exercise program
showed improved flexibility, coordination and breath volume in patients after completion of the
program (Peacock, 1987). A similar study which implemented a 14 week home rehabilitation program
on a male HD patient resulted in improvements in his Berg Balance Score by 9 points and in functional
measures of walking and speech, with improvements in dystonia, chorea and bradykinesia, and a
reduction in the number of falls (Quinn and Raio, 2002). This study suggested that physical therapy in
HD could improve function and the observed reduction in falls could significantly delay nursing home
placement.
Taken together, these results present environmental enrichment or physical exercise as a promising
therapeutic strategy to delay onset, and ameliorate symptoms in HD patients. Environmental enrichment
differs from currently prescribed pharmacotherapies in that it could potentially provide substantial
global benefits while doing no harm. This study will quantitavely assess the capacity of environmental
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enrichment to effect global physiological changes in HD patients, using specific biomarkers present in
peripheral blood and saliva. These biomarkers have been chosen as they are indicative of pathways and
physiological processes known to be affected in HD.

4. BRAIN-DERIVED NEUROTROPHIC FACTOR

4.1. BDNF in HD
BDNF is an abundant member of the neurotrophin family of proteins. BDNF acts in a paracrine and
autocrine manner to control a variety of brain processes including the growth, development,
differentiation and maintenance of neuronal systems, neuronal plasticity, synaptic activity and
neurotransmitter mediated activities (Zuccato et al., 2011). These effects are mediated by the binding of
BDNF to its specific receptors such as tyrosine receptor kinase B (TrKb) and p75 neurotrophin receptor
(p75NTR) (Altar et al., 1997). In the brain, BDNF is active in the hippocampus, cortex, and striatum,
areas vital to learning, memory, higher thinking, movement and control (Zuccato et al., 2011). BDNF
itself is important for long-term memory, and plays an important role in enhancing synaptic plasticity in
the brain, particularly during learning and memory, and is thus involved in preventing cognitive decline
throughout life (Zuccato et al., 2011).
Normally, the striatum of the brain is known to be rich in BDNF protein yet low in BDNF-mRNA.
Conversely, the substantia nigra and cerebral cortex have been found to be rich in BDNF mRNA (Fusco
et al., 2003). BDNF is synthesised in the cortex and colocalises with HTT protein in cortical neurons
that project to the striatum (Fusco et al., 2003). Although some studies have shown BDNF mRNA
transcription in adult striatal neurons (Hofer et al., 1990), 95% of striatal BDNF is of cortical origin.
BDNF is anterogradely transported from the cortex to the striatum in vesicles along the cortico-striatal
afferents (Fig. 4) (Altar et al., 1997).
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Figure 4: BDNF and the cortico-striatal synapse.
The orange arrows depict BDNF anterograde and
retrograde transport between the cortex and the
striatum of the brain. 95% of striatal BDNF is
synthesised in the cortex and anterogradely
transported to the striatum. Normal HTT protein
modulates the transport of BDNF along the corticostriatal afferents and in HD this transport is
dysregulated due to expression of the mutant form
of the HTT protein (Zuccato et al., 2007).

BDNF deficits are most profound in the striatum of HD patients, and as detailed below, this is
attributable to both the reduced cortical synthesis of BDNF and impaired transport of BDNF along the
cortico-striatal afferents (Zuccato et al., 2001, Gauthier et al., 2004). Moreover, the loss of BDNF has
been shown to worsen the HD phenotype and BDNF administration restores function and is
neuroprotective to toxic stimuli (Gharami et al., 2008, Kells et al., 2004).

Post moretem analysis of human HD brain tissue has shown lowered BDNF mRNA and protein levels
in the cerebral cortex, indicating reduced production of BDNF in HD patients (Baquet et al., 2004).
Overexpression of the normal HTT protein stimulates cortical BDNF production by acting on the level
of BDNF gene transcription in vivo and in vitro (Zuccato et al., 2008). Increased cortical BDNF in mice
caused elevated levels of BDNF in the striatum; this effect is lost in mice that over express mHTT
protein (Zuccato et al., 2008). Another study in which one BDNF allele was inactivated in a transgenic
mouse line with an expanded CAG repeat, demonstrated a worsening of the HD phenotype, with an
earlier age of onset and exacerbated behavioural deficits (Canals et al., 2004).

BDNF vesicular transport along the cortico-striatal afferent pathway has been shown to be significantly
reduced in cells that express mHTT. HTT has been found to be part of the motor complex which drives
anterograde transport of BDNF vesicles along the microtubules, and this motor complex is altered in
HD (Gauthier et al., 2004). Moreover, increasing BDNF levels in the striatum confers neuroprotection
against excitotoxic insult (Husson et al., 2005, Kells et al., 2008, Bemelmans et al., 1999).

Studies involving genetically engineered mice which were deficient in BDNF only in the cortex,
showed that these animals gradually developed brain damage and displayed a significantly smaller
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striatal volume, reduced soma size, thinner dendrites and fewer dendritic spines than WT littermates
(Baquet et al., 2004). Furthermore, these mice have also been shown to exhibit striatal gene expression
abnormalities which are very similar to those described in human post mortem HD striatum (Strand et
al., 2007). In contrast, a study in which BDNF was constitutively overexpressed in the striatum and
cortex of HD-affected mice substantially ameliorated motor dysfunction, reversed brain weight loss,
restored tyrosine receptor kinase B signalling in the striatum and reduced the formation of mHTT
aggregates in neurons (Gharami et al., 2008). Other studies in which BDNF was delivered via an
adenoviral vector to HD-affected mice demonstrated an improvement in motor impairment, in
comparison to untreated mice (Bemelmans et al., 1999, Kells et al., 2008). These results demonstrate
that cortical BDNF depletion is a major contributing factor to the pathogenesis of HD and that BDNF
serves as a profound therapeutic target in the treatment of HD.

4.2 Environmental Enrichment and its Effects on BDNF
Extensive studies have consistently demonstrated that environmental enrichment and voluntary exercise
are associated with the transcriptional upregulation of genes encoding neurotrophins which are essential
for neurogenesis, learning and memory (Rampon et al., 2000). Upregulation of BDNF expression in the
cortex has been reported in response to environmental enrichment (Falkenberg et al., 1992, Pham et al.,
1999, Keyvani et al., 2004). A compelling study conducted by Spires and colleagues which examined
BDNF levels in HD mouse models subsequent to environmental enrichment showed that the BDNF
protein deficits in the striatum and hippocampus observed in HD mice were entirely rescued after
environmental enrichment (Spires et al., 2004). Furthermore, delayed onset and decline of cognitive
ability has been demonstrated in mice after environmental enrichment (Pang et al., 2006). Taken
together, these findings indicate that the favourable effect of environmental enrichment on neurogenesis,
and neuroprotection may in part be attributed to its ability to restore BDNF levels in HD. Environmental
enrichment is therefore a promising approach for delaying onset of HD and associated cognitive and
physical decline. Confirmation of these results in human HD models are urgently needed however, in
order for this approach to be integrated into current HD therapies.
Because BDNF is able to cross the blood brain barrier and studies carried out in rodents have shown a
tight correlation between brain and blood BDNF values (Karege et al., 2002), it has been suggested that
blood BDNF levels in humans may reflect BDNF levels in the brain (Karege et al., 2002). Therefore the
examination of whole blood samples for levels of BDNF before and after environmental enrichment
would be useful in investigating if these results are replicated in human HD patients, and will provide us
with a biochemical marker to illustrate the physiological effects of environmental enrichment in HD
patients.
14

5. CORTISOL
5.1. Cortisol in Huntington’s Disease
Cortisol is a glucocorticoid that is synthesised from cholesterol in the zona fasciculata of the adrenal
gland in response to stress and low levels of blood glucocorticoids (Gallagher et al., 1973). Synthesis of
cortisol is regulated by corticotrophin-releasing hormone (CRH) released by the hypothalamus, which
stimulates production of adrenocorticotrophic hormone (ACTH) from the anterior lobe of the pituitary
gland, which in turn stimulates the adrenal cortex. When blood cortisol levels are restored, the release of
CRH is inhibited (Parker, 1991). The main functions of cortisol are to increase blood sugar levels
through glycogenolysis and reduction of glucose uptake into cells, suppression of the immune system,
and to aid in fat, protein and carbohydrate metabolism (Gallagher et al., 1973).
Neurodegenerative disorders including Alzheimer’s and Parkinson’s disease are associated with
neuroendocrine disturbances, and reflect changes in the hypothalamic-pituitary- adrenal (HPA) axis
(Wulff et al., 2010).
Neuroendocrine cell loss and hypothalamic atrophy are evident in HD (Petersen and Bjorkqvist, 2006,
Aziz et al., 2007) and studies in mouse models of HD have reported progressive alterations in the
hypothalamic-pituitary-adrenal (HPA) axis (Bjorkqvist et al., 2006). Furthermore, these mice have
shown progressive increases in cortisol levels which are accompanied by a Cushing-like syndrome
(Bjorkqvist et al., 2006). Numerous studies have also reported elevated cortisol levels in HD patients
(Leblhuber et al., 1995, Heuser et al., 1991, Bruyn et al., 1972). Cortisol levels have been correlated
with disease progression in HD patients and elevated cortisol levels may be relevant to mood changes
and some of the cognitive deficits that occur in HD (Aziz et al., 2009a).
Figure 5: Morning salivary
cortisol levels in relation to
waking
in
acutely
depressed subjects (n=20)
and
controls
(n=40).
Values are given as
mean±SEM.
*Patients
have
significantly
increased levels of salivary
cortisol at 15 min (t=−2.21,
p=0.036), 30 min (t=−2.22,
p=0.030), and 45 min
(t=−2.36,
p=0.022)
compared with controls
(Bhagwagar et al., 2005).
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Chronic stress and depression observed in HD patients may also contribute to alteration in the HPA axis.
It has been widely reported that depression and anxiety are associated with activation of the HPA axis,
which is measured by the plasma concentrations of cortisol (Marashi et al., 2003, Claustrat et al., 1984,
Halbreich et al., 1985). Abnormal activity of the HPA axis has been implicated as a feature of anxiety
and depressive disorders, and the association between elevated cortisol and depression has been well
replicated (Fig. 5) (Harris et al., 2000, Bhagwagar et al., 2005). Therefore the elevated levels of cortisol
seen in HD could be attributed to either a gain of function of mHTT in HD whereby mHTT could be
directly affecting the hypothalamus or pituitary gland. Alternatively or in addition to this, increased
cortisol levels in HD may be a secondary effect of depression and anxiety.
5.2. Environmental Enrichment and its effects on Cortisol
There is widespread evidence that environmental enrichment causes a transient spike in cortisol levels
which may be in response to the stress experienced by subjects after completing a cognitive or physical
test (Robertson et al., 1981, Christensen and Galbo, 1983, Gleeson et al., 2011). The long term effects of
environmental enrichment on cortisol levels however, are yet to be studied.
Physical exercise has been demonstrated to alleviate depression and anxiety (McDonald and Hogdon,
1991, Craft and Landers, 1998, Salmon, 2001). We expect these results will be replicated in HD patients
after environmental enrichment. We hypothesise therefore, that environmental enrichment will partially
restore the normal function of the HPA axis, which we will measure from salivary cortisol levels, and
we predict that salivary cortisol levels will normalise in response to environmental enrichment. A slight
improvement in depressive symptoms has already been observed in patients after a nine month
environmental enrichment study (Fig. 6) and we hypothesise that this trend will continue with a
prolonged environmental enrichment program of eighteen months. Evidence of these changes were
assessed by analysis of salivary cortisol levels in patients.
Figure
6:
Beck
Depression Inventory- II
Scores of HD patients
treated
with
environmental
enrichment
treatment
(Int) versus HD patients
without
intervention
(Ctl) at baseline and 9
months after baseline.
(Thompson et al., 2012).
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6. INSULIN

6.1. Insulin in HD
Insulin is a peptide hormone 51 amino acids in length that is synthesised in the beta cells of the
pancreas. Insulin is secreted within the body at a constant level to remove excess glucose from the
blood, which otherwise would become toxic. A constant state of hyperglycaemia is referred to as
Diabetes Mellitus (Charles, 1967).
Several studies have confirmed insulin abnormalities and a higher prevalence of diabetes in HD
patients. A study conducted by Podolsky and Leopold showed that 50% of HD patients (n= 14) had
impaired glucose tolerance after an oral glucose tolerance test (1977). A larger study conducted by
Farrer surveyed 620 HD patients and found that 10.5% had diabetes, which exceeded the age matched
population prevalence (1985). Furthermore, a decrease in insulin sensitivity with an increase in insulin
resistance has been found in HD patients (Lalic et al., 2008). Low insulin gene expression in the
pancreas of HD mouse models has also been demonstrated (Andreassen et al., 2002).
Insulin is transported into the CNS across the blood-brain barrier by an insulin receptor-mediated
process (Banks et al., 1997b, Banks et al., 1997a). Increasing peripheral insulin concentrations acutely
increases the concentration in the brain; conversely, prolonged peripheral hypoinsulinaemia reduces
insulin transport into the brain and downregulates blood-brain insulin receptors (Wallum et al., 1987).
Insulin receptors, although abundant in the brain, are selectively distributed in the cerebral cortex,
hippocampus, hypothalamus, amygdala, substantia nigra, basal ganglia and frontal cortex (Unger et al.,
1991). Insulin has been reported to influence memory (Singh et al., 1997), and studies have found that
intranasal administration of insulin increases memory performance in humans (Fehm et al., 2000).
Therefore hypoinsulinaemia may be a contributing factor to the memory loss observed in HD patients.
6.2. Environmental enrichment and its effects on Insulin
Physical exercise has been described as being fundamental to the management of diabetes (Sigal et al.,
2004). Improvement in glucose homeostasis and attenuation of insulin requirements in diabetic patients
after physical exercise is a well replicated finding (Tessier et al., 2000, Boule et al., 2001, Helmrich et
al., 1991). An increase in insulin sensitivity in exercised patients has been demonstrated, possibly
mediated by the upregulation of insulin receptors in these individuals (Pederson, 1980). The effect of
physical exercise on insulin is yet to be studied in HD patients. As insulin levels are dysregulated in
HD, as explained above, we aim to investigate insulin levels pre and post environmental enrichment and
we predict that the hypoinsulinaemia which may be observed in HD patients will be attenuated upon
completion of an environmental enrichment program.
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In summary, it is clear that biochemical markers analysed from peripheral blood and saliva are likely to
provide an estimate of the global features of HD and the effect of environmental enrichment on
physiological parameters.

7. Hypothesis
Environmental enrichment globally affects physiological processes in patients with Huntington’s disease
as evidenced by changes in biochemical markers representative of neural and neuroendocrine pathways,
and metabolic processes.
Aims
1. To investigate changes in peripheral BDNF levels in HD patients after an environmental
enrichment treatment, relative to HD controls.
2. To investigate changes to peripheral blood insulin levels in HD patients after environmental
enrichment treatment relative to HD controls.
3. To investigate changes in the HPA axis, identified by changes in salivary cortisol levels in HD
patients after environmental enrichment treatment, relative to HD controls.
8. Theoretical Framework
Environmental enrichment has been demonstrated to prolong age of onset and alleviate symptoms in
mouse models of HD. Physical exercise and short trials of environmental enrichment in HD patients
have also demonstrated effective modulation of symptoms. An 18 month trial of environmental
enrichment was completed at ECU by Thompson et al. (in press) in HD patients. This is the longest trial
of continual environmental enrichment treatment in HD to date. The physical, neurological and
cognitive changes as a result of this study were measured and results indicated amelioration of motor,
physical and cognitive symptoms. In the project described here, we investigated the physiological
effects of environmental enrichment in a quantitative manner, using biochemical markers to deduce
whether environmental enrichment has global physiological effects on patients.
Neural dysfunction in HD is well documented and is thought to occur in part as a result of BDNF
depletion. Physical exercise upregulates BDNF, therefore we will investigate whether BDNF losses in
HD can be ameliorated by environmental enrichment. Similarly the HPA axis has been observed to be
dysfunctional in HD and the secretion of cortisol, a marker of the HPA axis, is dysregulated in HD.
Physical exercise has been shown to restore HPA function. Here we assessed cortisol levels after
environmental enrichment treatment as a marker of HPA function in our patients, relative to HD
18

controls. Metabolic dysfunction is widely reported in HD and there have been some reports of impaired
glucose tolerance in the HD population, indicating dysregulation of the insulin pathway. Physical
exercise enhances insulin sensitivity by upregulating insulin receptors, therefore we will assess whether
insulin levels in HD can be amended by an environmental enrichment treatment program.
9. METHODS
9.1. Research Design and Methodology
Twenty five symptomatic HD patients were recruited by Dr Jennifer Thompson of the HD group at
Edith Cowan University, in collaboration with the Neurosciences Unit North Metropolitan Area Mental
Health Service (NMAMHS). Ethical approval for the study of HD patients before, during and after an
eighteen month environmental enrichment program has been granted by the Human Research Ethics
Committees of Edith Cowan University and the North Metropolitan Area Mental Health Service.
Patients provided informed consent to participate in the study.
9.1.2. Participants
Potential participants were identified and recruited utilising NMAMHS databases. Inclusion criteria
consisted of a positive genetic test, clinical disease diagnosis (UHDRS-TMS ≥ 5), ability to follow
verbal or written instructions and the capacity to perform sub-maximal exercise. Exclusion criteria
included recent substance abuse, an unstable psychiatric or medical condition, or confounding
neurological conditions. Each patient was given a Z score for cognitive and motor ability at baseline.
Patients were then assigned to two groups equally matched for cognitive and motor Z scores to reduce
any confounding effects due to differences between groups. Age, gender, age at diagnosis, disease
duration, CAG repeat number, CAG index and BMI differences were analysed and no significant
differences (p > 0.05) between the two groups were found for these variables at baseline (Table 2). As
these covariates were already controlled for at the beginning of the study, it is not necessary to analyse
their effect on the markers used in this investigation. Participants were randomised to an intervention
group (IG) or delayed intervention group (DIG) as explained below. It was not possible to blind
participants to group allocation.
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Table 2: Outline of covariate measures of the Intervention and Delayed Intervention Group. No significant
difference was found between the two groups in relation to the variables indicated below (p > 0.05). (Thompson et
al., 2012)

Intervention Group (IG)
(mean ±SEM)

Delayed Intervention Group
(DIG)
(mean ±SEM)

9

11

Gender M/F

4/5

6/5

Age (years)

53.8 ± 2.9

52.2 ± 2.6

Age at Diagnosis (years)

49.5 ± 3.2

49.7 ± 2.5

Disease Duration (years)

4.3 ± 1.8

2.4 ± 0.7

CAG Number

43.1 ± 1.1

43.7 ± 0.7

CAG Index

399.0 ± 53.7

416.1 ± 23.3

Body Mass Index (kg/m2)

26.2 ± 1.3

27.1 ±

Characteristic
Number of participants

1.3

9.1.3. Medication: A thorough medical history and complete list of medications was taken at the
beginning of the study and at each assessment point for each patient. Participants remained on their
medication throughout the study, which was adjusted where necessary by physicians. All participants
were deemed fit to participate by a clinician.

9.1.4. Intervention Design
An interdisciplinary team comprised of neurologists, psychiatrists, psychologists, physiotherapists,
occupational therapists, and exercise physiologists were involved in the design of the intervention which
was formulated after the analysis and interpretation of baseline data. As HD is a highly variable disease,
the intervention was individually tailored in order to maximise safety and efficacy. Thereafter each
patient worked at their own capacity, and the intervention was progressed on an individual basis when
the exercise physiologists deemed individuals physically capable. There were also gender differences in
the ability of patients to perform the exercises. The implementation of a weekly aerobic and resistance
training program was carried out in an exercise clinic by exercise physiologists. Physiotherapists and
exercise physiologists designed and implemented a home-based program. Occupational therapists
formulated personalised programs that targeted deficits detected at baseline by psychologists.
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9.1.5. Intervention
The clinical gym exercise program consisted of nine months of once-weekly supervised group exercise
sessions conducted in a clinic gym setting. In order to reduce potential falls and to minimise the risk of
injury resistance training machines were utilised rather than free weight training. In order to maximise
patient compliance, a variety of times and locations were offered to minimise travel and lifestyle
constraints. Each exercise session included a 5 minute warm up period, 10 minutes of aerobic exercise,
40 minutes of resistance exercise and a 5 minute cool down period.

In addition, a personally tailored home-based exercise program including aerobic and resistance
exercise components was prescribed to patients, to be performed three times weekly. This program was
performed independently after precise instruction by the interdisciplinary team, and was not employed
until exercise physiologists deemed that the person was physically capable of performing it safely.
Personalised occupational therapy programs designed to maintain self-care, leisure and personal
independence were provided to patients on a weekly basis in the home environment.

In order to facilitate the standardisation of the clinical exercise sessions, monitor adherence and track
physical progression of patients, exercise physiologists were given an exercise manual to follow and a
logbook to record exercise data.

To maximise safety and increase compliance of the home-based program, an exercise DVD, manual and
diary were provided to all intervention participants. Exercise physiologists additionally reminded
participants to perform the home-based exercise program and complete their exercise diaries.

9.1.6. Physical and Neuropsychological Measures
A clinical battery of motor, cognitive, physiological and functional assessments were used to assess
patients. The UHDRS-TMS was used to assess changes in motor function. Additional outcome
measures assessed functional, cognitive, depressive and quality of life changes.

Body composition was quantified using a Hologic Dual X-ray Absorptiometry Scanner (DEXA).
Routine physical strength tests were used to assess changes in muscle strength. Postural stability
changes were examined using the Sensory Organisation Test (Neurocom SMART Balance Master,
NeuroCom). Neuropsychological tests included the Symbol Digit Modalities Test, Hopkins Verbal
Learning Test-Revised, Colour Word Interference Test and Trail Making Trials. The Goal Attainment
Scale examined achievement of goals. Levels of depression were assessed using the Beck Depression
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Inventory-II. Finally, quality of life perceptions of patients and carers were evaluated using the SF-36v2
Health Questionnaire and Huntington's Disease Quality of Life Battery for Carers (HDQOL-C).

In the study performed for this thesis, biomarkers indicative of physiological parameters were assessed
at baseline, during, and at the end of the study. The remainder of the methods and results will detail
these experiments.

10. QUANTIFICATION OF BIOMARKERS
10.1.
Aim 1: Quantification of BDNF in Patient Blood
Background
Measuring BDNF from patient brain tissue samples is not possible in our study. However, BDNF is able
to cross the blood brain barrier and it has been suggested that blood BDNF levels may reflect the BDNF
levels in brain (Trajkovska et al., 2007). Studies carried out in rodents have shown a tight correlation
between brain and blood BDNF values (Karege et al., 2002). We therefore measured BDNF from whole
blood samples. Moreover, recent literature has revealed that BDNF is better assessed in whole blood
than in serum when samples are stored for extended periods of time. Long term storage of serum
samples (6 - 10 months) has been associated with significantly lower serum BDNF concentrations
which suggest that in whole blood samples, BDNF stored in platelets is protected from degradation
(Trajkovska et al., 2007).
To measure BDNF, non-fasting blood samples were obtained from patients at 0, 9 and 18 months by
venipuncture of the antecubital vein and collected into EDTA blood tubes. Samples were collected from
all patients over 2 days, within two weeks upon completion of the study. BDNF has a diurnal rhythm ,
with variation between males and females (Fig. 7) (Piccinni et al., 2008), therefore utmost care was
taken to obtain samples from patients at midday (12.30- 2.00pm), when male and female BDNF levels
cross over.
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Figure 7:
Plasma BDNF levels at three time-points in both
males (n= 14) and females (n=14). In males,
plasma BDNF concentrations (mean+SD, ng/ml)
were 7.82+5.61 at 08:00 h, 5.49+4.34 at 14:00 h,
and 3.52+2.75 at 22:00 h. In females, BDNF
levels were 5.48+2.26 at 08:00 h, 5.80+2.67 at
14:00 h, and 5.71+3.79 at 22:00 h. Significant
diurnal variation in plasma BDNF concentration is
evident in males (p = 0.008) (Piccinni et al., 2008).

Method
BDNF was analysed in whole blood which was taken from patients at 0, 9 and 18 months of the study.
Samples were not centrifuged as this would rupture thrombocytes and release BDNF into the serum,
where it may be subjected to proteolysis (Trajkovska et al., 2008). Whole blood samples were stored at
-20°c until required.
When samples were ready to be measured, blood was thawed, inverted several times and 3% TritonX100 was added to disrupt the cell membrane of the thrombocytes. The mixture was then sonicated for
10 seconds at output 3 of the sonicator, to further rupture the cell membranes. The time and intensity of
sonication was determined for optimal release of BDNF into the serum, and details of this optimisation
are explained in Table 7. The samples were then centrifuged to separate the plasma and the plasma was
tested for BDNF using the BDNF BEK-2002-2P sandwich ELISA Kit (Biosensis, Ukraine), which was
modified for use in our laboratory as follows:
The standards were prepared and 100µL of the standards, controls and plasma samples were pipetted
into the microtiter wells of a 96 well plate which were pre-coated with polyclonal human BDNF
antibody. A 1:10 dilution of the plasma samples was made before samples were added to the wells.
Samples, standards and controls were measured in duplicate. The plate was sealed with parafilm and left
to incubate overnight at 4°C on a plate shaker. The plate was then washed five times with pre-prepared
wash buffer (0.85% NaCl, 0.14% Na2HPO4, 0.02% NaH2PO4, 7.2<Ph<7.6). 1000uL of biotinylated
antibody solution was added to each well. This solution contained a detection antibody which bound to
the antigen, thus completing the ‘ELISA sandwich’. The plate was sealed and incubated at room
temperature on a plate shaker for 3 hours. The plate was then washed five times, after which 1000µL of
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1:99 Avidin-Biotin-Peroxidase Complex (ABC) working solution diluted with ABC buffer was added to
each well. The plate was sealed and incubated on a plate shaker for an hour. The plate was then washed
five times with wash buffer after which 90µL of the peroxidase substrate, tetramethylbenzidine (TMB)
colour developing agent was added to each well and left to incubate for 5-20 minutes. Thereafter, 100µL
of TMB stop solution was added to each well to halt the reaction. The intensity of the coloured product
is directly proportional to the concentration of BDNF present in the samples. The absorbance of each
well was read at 450nm using a Fluostar II (BMG LAB TECH) absorbance reader within 10 minutes of
the addition of stop solution. Concentrations of BDNF in patient samples were determined from the
standard curve of absorbance readings of standards provided in the kit.
10.2.
Aim 2: Quantification of Insulin in Patient Blood
Background
In order to quantify insulin levels in patients, we measured C-peptide (Fig. 8) levels in fasting plasma
samples from HD patients taken at 0, 9 and 18 months of the environmental enrichment program.
Samples were collected from all patients over 2 days. Fasting blood samples were taken as this provides
an accurate baseline measurement of insulin levels, unaffected by food ingestion.

Figure 8: Insulin is synthesised in pancreatic beta
cells as a component of proinsulin. Proinsulin is
enzymatically cleaved releasing insulin into the
circulation along with a residual fragment,
Connection - peptide (C-peptide). Thus, C-peptide
is present in equimolar amounts with insulin
(http://medicaldictionary.thefreedictionary.com/ins
ulin).

Measurements of C-peptide were taken because the half life of C-peptide is between 2 and 5 times
longer than that of insulin (Horwitz et al., 1975). Furthermore, C-peptide is metabolically inert, with Cpeptide levels in venous blood approximately 5-6 times greater than that of insulin levels (Beyer et al.,
1979). Another advantage to using an insulin assay is that a C-peptide assay is able to distinguish
endogenous insulin from injected insulin. A C-peptide ELISA kit (DE1293) (DEMEDITEC) was
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utilised to measure C-peptide levels, and the methodologies described in the ELISA kit manual were
adapted for our studies as follows:
Method
Patient blood was drawn from the antecubital vein by venipuncture, collected into EDTA tubes and
centrifuged immediately to separate the plasma. The plasma was aliquoted and stored at -20°C until
used in this project.
Thawed samples were inverted several times prior to testing. 100µL of each standard, control and
sample were dispensed into a 96 well microtiter plate pre-coated with anti-mouse antibodies to Cpeptide. Each standard, control and sample was measured in duplicate. Each sample was combined with
50µL of anti-serum, a monoclonal anti C-peptide antibody and 100µL of enzyme conjugate. The
mixture was mixed then incubated at room temperature for 60 minutes with shaking at 400-500 rpm.
The wells were then emptied and washed three times with 400µL of diluted wash solution. 100µL of
enzyme complex was then added to each well and the wells were incubated for 30 minutes at room
temperature with shaking at 400 rpm. The wells were then washed again as described above and 100µL
of substrate solution was added to each well. This was followed by an incubation period of 20 minutes
at room temperature after which the enzymatic reaction was halted by the addition of 100µL of stop
solution (1 mol/L H2SO4). The intensity of colour observed was inversely proportional to the
concentration of C-peptide in the patient sample. The absorbance of each well was determined using a
Fluostar II (BMG LAB TECH) absorbance reader at 450 nm within 10 minutes of adding the stop
solution. Patient concentrations of C-peptide were derived from the standard curve obtained from the
absorbance readings of the standards provided in the kit.

10.3.
Aim 3: Quantification of Cortisol in Patient Saliva
Background
Cortisol was measured from saliva samples taken at six specific times during the day over 3 consecutive
days to capture the diurnal rhythm (Fig. 9), with levels peaking in the early morning and dropping to the
lowest values at night (Hucklebridge et al., 2005). Levels of cortisol rise independently of circadian
rhythm in response to stress (Miller et al., 2007).
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Figure 9: Cortisol
production has
a
diurnal rhythm with
levels peaking early in
the
morning
and
dropping to their
lowest values at night
(Abudu, 2009).

Salivary cortisol levels were measured in our project because studies have consistently reported a high
correlation between salivary and serum cortisol levels (Dorn et al., 2007), which indicates that salivary
cortisol levels are a reliable measure of serum cortisol levels. Moreover, salivary cortisol levels are not
affected by salivary flow rate and are relatively resistant to degradation from enzymes or freeze thaw
cycles (Vining and McGinley, 1987, Garde and Hansen, 2005). Blood samplings require mildly invasive
techniques that may cause stress and thereby alter HPA axis activity (Stahl and Dorner, 1982),
additionally, cortisol in blood is largely bound to plasma proteins (Angeli et al., 1978) whereas salivary
cortisol has been shown to be correlated with plasma free cortisol, the biologically active fraction (Katz
and Shannon, 1969). Due to the diurnal rhythm of cortisol secretion, we assessed cortisol levels at six
time points. For this reason it was also more practical to assay cortisol in saliva rather than blood
samples.
Method
Saliva samples were taken from patients using Salivette tubes (SARSTEDT) over three consecutive
days at the times specified in Table 3. As cortisol levels have been reported to have the greatest
variability overnight between HD patients (van Duijn et al., 2010), morning and evening cortisol levels
were averaged from two overnight samples.
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Table 3: Outline of the various times saliva
samples were taken from patients. Two
overnight readings were taken as it has been
speculated that overnight readings are the most
variable amongst HD patients.
Day

Time

1

20:00 hrs

2

08:00 hrs
12:00 hrs (before consumption of lunch)
16:00 hrs
20:00 hrs

3

08:00 hrs

Saliva samples were taken at 0, 9 and 18 months of the environmental enrichment program. Food or
drinks, with the exception of water were not consumed by the patients 1 hour prior to taking the saliva
sample and smoking was not allowed for the 30 minutes prior to providing the sample. Patients
refrained from consuming alcohol 12 hours prior to commencement of measurement of saliva samples.
Salivette tubes containing saliva samples were frozen at -20°C by patients.
In this study, salivary cortisol levels were quantified by using a High Sensitivity Salivary Cortisol
ELISA KIT 1-3002 (SALIMETRICS). The protocol was adapted in our study as follows:
All reagents and saliva samples were brought to room temperature before use. Saliva samples were first
vortexed for 10 seconds before they were centrifuged for 15 minutes at 3000 rpm. A 1X wash buffer
was then prepared from the 10X wash buffer included in the kit. Duplicates of standards, controls and
samples were pipetted into the wells of a 96 well microtiter plate provided in the ELISA kit, pre-coated
with monoclonal antibodies to cortisol. Cortisol enzyme conjugate (cortisol linked to horseradish
peroxidase) was then added to each well, followed by 60 minutes of incubation on a plate shaker. The
wells of the plate were then washed four times with wash buffer, to wash away any unbound
components, before the addition of TMB substrate solution to measure the bound cortisol peroxidase.
The plate was shaken for 5 minutes and then incubated for 25 minutes in the dark. After incubation,
50µL of stop solution was added to each well, the plate was then shaken for 3 minutes again. The
absorbance of each well was read at 450nm using a Fluostar II (BMG LAB TECH) absorbance reader
within 10 minutes of the addition of stop solution. The amount of cortisol peroxidase was measured by
the intensity of colour which was inversely proportional to the amount of cortisol present. A standard
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curve was prepared from the absorbance readings of standards provided in the kit, and concentrations of
cortisol in patient saliva samples were estimated from the standard curve.
11. DATA ANALYSIS
The concentrations of the above biomarkers were obtained at baseline, 9 months and 18 months after
intervention. The differences in levels of each biomarker between baseline, 9 months and 18 months
were calculated for each participant. These values were then averaged to obtain a mean and standard
error of the mean (SEM) for each group over each different time period. Results were analysed using a
one way ANOVA to assess statistical significance (Fig. 10). A p value ≤ 0.05 was deemed statistically
significant. Below is a schematic detailing the timeline of the intervention and the analysis of the results
in the 2 different groups.

Baseline
Measurements taken
from all patients

9 Months
Measurements taken
from all patients

18 Months
Measurements taken
from all patients

9

9

9

Time 0

Intervention Group (IG) received
intervention for 9 months

Intervention Group (IG) received
an additional intervention for 9
months

Delayed Intervention Group (DIG)
underwent a control period of 9
months

Delayed Intervention Group
(DIG) received intervention for 9
months

Time 1

Time 2

Figure 10: Schematic outlining the different participant groups in our study. The delayed intervention group
(DIG) (blue) were tested for baseline measures at Time 0 and did not receive environmental enrichment
treatment for 9 months (a control period). Thereafter, intervention was provided for 9 months from Time 1 Time 2. The intervention group (IG) (red) were tested for baseline measures at the beginning of the study,
Time 0, and were given 2 rounds of intervention, therefore receiving a total of 18 months of intervention with
measures taken at Time 1 and at the end, Time 2. By using this study design we are able to study the effects of
intervention versus HD controls (no intervention) as well as compare the effects of a longitudinal intervention
relative to a shorter intervention. We also compared results for controls (no intervention) relative to those after
18 months of intervention.
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12. RESULTS
Current pharmacological therapies prescribed to HD patients act merely to manage symptoms, and do
nothing to delay the onset or rate of decline of this fatal disease. These therapies are not specifically
designed for HD but for the general symptoms observed in HD and have a large range of side effects
(Tabrizi et al., 2011). Environmental enrichment has proven successful in delaying onset and symptom
progression in mouse models of several neurodegenerative disorders including Parkinson’s and
Alzheimer’s disease (Goldberg et al., 2012, Jeong et al., 2011, Rodriguez et al., 2011). Furthermore,
several studies in mouse models of HD have demonstrated delayed onset, improvement in motor
symptoms, slower rate of disease progression, amelioration of cerebral volume degeneration and
behavioural improvements (Hockly et al., 2002, Lazic et al., 2006, Spires et al., 2004, van Dellen et al.,
2000). In humans, short trials of environmental enrichment in HD patients have shown promising
results including improved physical, social, psychological and motor function and depression scores
(Sullivan et al., 2001, Zinzi et al., 2007). Taken together, environmental enrichment is a promising
therapeutic strategy to delay onset and ameliorate symptoms in HD, with potential global physiological
effects.
An 18 month environmental enrichment intervention was conducted by ECU researchers. This study is
the longest trial of continual environmental enrichment in HD to date. In this study we investigated the
effects of environmental enrichment on physiological processes which are dysregulated in HD. Here we
describe analysis of changes in levels of biochemical markers as evidence of the global physiological
effects of environmental enrichment on HD patients. Three biochemical markers were used to analyse
these changes on physiological processes; BDNF, insulin and cortisol.
Neural dysfunction in HD is thought to occur in part due to BDNF depletion (Zuccato et al., 2001). As
physical exercise upregulates BDNF (Falkenberg et al., 1992, Keyvani et al., 2004, Pham et al., 1999),
we investigated whether BDNF protein levels in HD patients are affected by environmental enrichment.
Metabolic dysfunction is widely reported in HD, and impaired glucose tolerance in the HD population
has been widely demonstrated, indicating the dysregulation of insulin in these patients (Lalic et al.,
2008). Physical exercise enhances insulin sensitivity by upregulating insulin receptors, therefore we
assessed whether insulin dysregulation in HD can be amended by an environmental enrichment
treatment program. Insulin was indirectly assessed by measuring levels of C-peptide (as described in
section 8.2). Similarly the HPA axis has been observed to be dysfunctional in HD (Aziz et al., 2009b,
Bjorkqvist et al., 2006) and the secretion of cortisol, a marker of the HPA axis, is known to be
dysregulated in HD (Aziz et al., 2007, van Duijn et al., 2010). Physical exercise has been shown to
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restore HPA function (Salmon, 2001). Here we assessed cortisol levels after environmental enrichment
treatment as a marker of HPA function in our patients.
At the beginning of the environmental enrichment study, baseline measurements of all participants were
taken, after which patients were divided into either an intervention group (IG), or a delayed intervention
group (DIG). The IG, (represented in red in graphs), underwent the intervention for the first 9 months of
the study. Thereafter they received a further 9 months of intervention, i.e. a total of 18 months of
intervention. The DIG, (represented in blue in graphs) underwent a control period (no intervention) for
the first 9 months of the study, followed by 9 months of optimised intervention (Fig. 10). The details of
the intervention and the timeline for each group are described in Table 4 and Fig. 10 respectively.
Table 4: Details of the intervention provided to the DIG and IG over the 18 month study period.

Intervention Group
(IG)

0 - 9 Months of the study

9-18 months of the study

(Time 0 - Time 1)

(Time 1 – Time 2)

IG received 9 months of intervention which

IG received an additional 9 months of

consisted of:

intervention (longitudinal intervention) which



1 x weekly supervised gym visit.



1

x

weekly

self-directed

consisted of:

home

based exercise.


1

x

weekly

home

visit



1 x weekly supervised gym visit.



1 x weekly self directed home based
exercises.

by

occupational therapist.
DIG received an optimised intervention which
DIG had no intervention:
Delayed

Control Period in which patients

Intervention Group

carried out their normal day to day

(DIG)

consisted of:


1 x weekly supervised gym visit.



1 x weekly exercise physiologist-

activities

supervised home based exercise.


1 x weekly home visit by occupational
therapist.
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12.1. BDNF Levels in Response to Environmental Enrichment:
Whole blood samples were sonicated at output 3 on the sonicator for 10 seconds as this was found to be
the optimal protocol for maximal BDNF release, without causing damage to the BDNF protein (See
Table 5 for summary of sonication optimisation). Samples were analysed for BDNF using the BDNF
BEK-2002-2P sandwich ELISA KIT (Biosensis, Ukraine). The details of the method are described in
section 8.1. Samples were run in duplicate in the same assay. Intra-assay CV was 2.4%, and the interassay CV was 4.45%.
Table 5: BDNF optimisation to identify the optimal time of sonication, output level and dilution factor of sample using the probe
or water bath method. Blood used for sonication attempts was obtained from a healthy female.
Attempt

Aim

Conditions

Time

Dilution Factor

Outcome

(Whole Blood: 3%
Triton X)

1

To investigate the sonication

Sonicator probe

15 s, 30s,

procedure by examining a range of

at Output 3

45s and 60s

1:2

(600ul

sonication times



High background reading



Obtained BDNF concentrations 5 x lower
than normal range

sample)


Standard curve was inaccurate (r=0.89)



45 s blood sample coagulated after
sonication

2

3

To investigate the use of a water

Water Bath

30 s, 45 s,

bath sonicator as all samples are able

sonicator at

60 s

to be sonicated at one time.

80% output

To improve yield by increasing

Water Bath

1.5 min, 2

intensity and time of sonication

sonicator at

min, 2.5

BDNF concentrations obtained in

100% Output

min, 5 min,

1:2



Obtained BDNF concentrations that were
10x below normal expected range

1:2



Obtained BDNF concentrations that were
10x below normal expected range

7min,

attempt 2 were too low.

10min

4

To investigate probe sonicator again

Probe sonicator

10s, 15s,

as water bath sonication method still

at output 3

30s, & 45 s

1:2 and 1:10



1:10 dilution with 10 s sonication at output
3 yielded BDNF concentrations closest to

yielded BDNF concentrations too

normal expected range.

low even at highest intensity for
prolonged time of sonication. A
more diluted sample was used as
ELISA kit may not be able to detect
concentrated BDNF levels

5



A range of outputs and times around

Probe sonicator

the 10s mark were investigated as

at Ouput 3, 4, 5

for 10s still yielded the BDNF concentration

1:10 dilution with probe- sonication

and 6

closest to normal range (Fujimura et al.,

8s, 10s, 12s

1:10

1:10 dilution with probe sonication at output 3

at output 3 for 10 s yielded the best

2002), therefore these conditions were utilised

result in attempt 4.

in analysing patient samples.
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Baseline levels of BDNF were not significantly different between the DIG and the IG (p>0.05) and were
below the normal expected range (Fig.11a). In the DIG, a gradual decrease in BDNF levels was seen in
patients over time; BDNF levels decreased during the 9 month control period and this trend was also
seen during the 9 month intervention. These changes were not statistically significant (p>0.05).
In the IG, a significant decrease in BDNF levels was observed during the first round of intervention
(p=0.03). Interestingly, BDNF levels increased slightly upon completion of the second round of
intervention relative to levels at 9 months, but the increase was not significant (p>0.05). After 9 months
of intervention, BDNF levels were significantly lower (p = 0.011) in the IG compared to the DIG which
underwent a 9 month control period during this time (Fig. 11a, Table 6).

20000

BDNF Levels at Each Time Point in DIG vs IG

18000

BDNF Concentration (pg/mL)

16000
14000
12000
10000
8000
6000

DIG
IG
Normal

4000
2000
0
1

2

3

Figure 11a: BDNF concentrations from whole blood at 0 Months, 9 Months and 18 Months after the
commencement of the study in the DIG (blue) and the IG (red). The blue dashed line indicates the 9 month
control period in the DIG. The grey shaded area represents the normal expected range for BDNF concentrations.
Values are presented as mean ± SEM *P < 0.05. DIG (n) = 10 IG (n) = 8.

In order to reveal the relative changes in BDNF levels, the differences in BDNF levels between time
points were calculated (Fig. 11b, Table 6). During the 9 month control period in the DIG, BDNF levels
decreased slightly by an average of 816 pg/mL. Similarly, a slight decrease in BDNF levels was also
seen in this group after 9 months of intervention, although these decreases were not statistically
significant (p>0.05).
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In the IG, a decrease in BDNF levels by 4 652 pg/mL was also seen after the first round of intervention.
By contrast, after the 18 month longitudinal intervention in this group, a significant increase in BDNF
levels was observed (p=0.03).
BDNF levels decreased from baseline by an average of -3 276 ± 1184 pg/ml after one round of 9
months of intervention in both groups.

Difference in BDNF Levels Between Time
Points in HD Patients

BDNF Concentration (pg/mL)

6,000
4,000
2,000
0
2,000
4,000
6,000
8,000

Control (DIG)

Intervention (DIG) Intervention (IG) Intervention (DIG + Longitudinal
IG)
Intervention (IG)

Figure 11b: The mean difference in whole-blood BDNF concentrations after a 9 month control period in the
DIG (blue), 9 months of intervention in IG (red) and the DIG (blue), after 9 months of intervention in both
groups was combined (purple) and after 18 months of longitudinal intervention in the IG (red). Values are
presented as mean ± SEM *P < 0.05. DIG (n) = 10 IG (n) = 8.
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Table 6: Mean BDNF concentrations at each time point in the DIG (blue) vs the IG (red) and P Values after 2-way Repeated
Measure ANOVA analysis. Values are represented as mean ± SEM.
Mean BDNF Concentration

Mean Difference Between

P Value (2 Way Repeated Measures

Time Points (pg/mL ± SEM)

ANOVA)

(pg/mL ± SEM)

Time 0

Time 1

Time 2

Time 1 –

Time 2 –

Time 2 –

Time 0

Time 1 vs Time

Time 2 vs

Time 0

Time 1

Time 0

vs Time

2

Time 0

1

IG

13 095 ± 2 111 8 443 ± 847 10 423 ± 2
174

DIG

12 333 ± 1
450

11 661 ±
880

9 966 ± 740

P Value

0.25

0.01

0.41

-4 652 ±
951

2 352 ± 2
233

-1 261 ± 2 096

0.03

0.19

0.20

-816 ± 935

-2 052 ± 1
033

-2748 ± 1219

0.41

0.08

0.27

(2 Way
ANOVA)
IG vs DIG

As mentioned earlier, BDNF levels vary between males and females, therefore we aimed to investigate
BDNF levels in males and females separately. Both male and female BDNF levels were below the
normal expected range for each gender (shown in triangles in Fig. 11c) (Trajkovska et al., 2007).
In both the IG and the DIG BDNF levels in females were observed to fluctuate particularly after either
the control or intervention periods, whilst levels remained relatively stable in males throughout the
study. This can be seen by the difference in patterns represented by the pink (females) and green (males)
lines in Fig. 11c.
In the DIG at 0 months, and after the 9 month control period, BDNF levels were significantly higher in
females compared to males (p=0.05 and p=0.005 respectively). After 9 months of intervention in this
group, female BDNF levels decreased to levels similar to those seen in males (this decrease was not
significant p>0.05), and by the end of the study at 18 months, levels did not differ between males and
females (p>0.05).
In the IG, levels of BDNF did not differ significantly between males and females throughout the entirety
of the study (p > 0.05). After the first 9 months of intervention in this group, BDNF levels decreased in
both males and females and after 18 months of intervention BDNF levels rose sharply in females to
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16 126 pg/mL, this rise however was not significant (p>0.05). After 18 months of longitudinal
intervention in this group, males and females appeared to respond differently.

Mean BDNF Levels in Males and Female HD
Patients over 18 Months
20,000
BDNF Concentration (ng/mL)

18,000

16,000

Females DIG
Males DIG
Females IG
Males IG
Normal Females
Normal Males

14,000
12,000
10,000
8,000
6,000
4,000
2,000
0

0

1

2

Figure 11c: Mean whole blood BDNF concentrations in males (green) and females (pink) at each time
point in the study. Normal expected values for females are represented in pink (▲) and normal expected
values for males are shown in green (▲). The DIG is shown in blue (●) and the IG is shown in red (■).
The 9 month control period is represented by a dashed line in the DIG. Values are presented as mean ±
SEM. DIG Females (n)= 6, Males (n)= 4. IG Females (n)= 2, Males (n)= 6.

To further investigate the BDNF gender response, the difference in BDNF levels between time points
was calculated separately for males and females (Fig. 11d). After the control period, BDNF decreased
in both males and females in the DIG, and after 9 months of intervention in this group, BDNF levels
continued to decrease in females, however increased slightly in males by an average of 750 ± 284
ng/mL. The male response was significantly different to the female response seen during the
intervention in the DIG (p=0.031).
After 9 months of intervention in the IG, a decrease in BDNF was seen in both males and females. After
an additional 9 months of intervention in this group, BDNF levels increased significantly in females
(p=0.026), and levels remained the same in males (p>0.05) relative to levels at 9 months of intervention.
There was a significant difference in the change in BDNF levels between males and females after the
longitudinal intervention (p=0.027). However, the increase in BDNF after the 18 month longitudinal
intervention in the IG was not significantly different to the decrease in BDNF levels seen during the 9
month control period in the DIG (p>0.05).
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Mean Difference in BDNF in Male and Female
Patients Between Time Points

BDNF Concentraion (ng/mL)

20,000
15,000
10,000

Females
Males

5,000

0
5,000
10,000
15,000
Control (DIG)

Intervention
(DIG)

Intervention (IG) Intervention (DIG Longitudinal
+ IG)
Intervention (IG)

Figure 11d: The mean difference in whole-blood BDNF concentrations in males (green) vs females (pink) after a
9 month control period in the DIG, 9 months of intervention in IG and the DIG, after 9 months of intervention in
both groups was combined and after 18 months of longitudinal intervention in the IG. Values are presented as
mean ± SEM *P < 0.05. DIG Females (n)= 6, Males (n)= 4. IG Females (n)= 2, Males (n)= 6.
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12.2. C-peptide Measurements in Response to Environmental Enrichment:
Analysis of fasting plasma was performed using a C-peptide ELISA kit DE1293 (DEMEDITEC) as
described in section 8.2. Samples were run in duplicate in the same assay. Assay results were considered
acceptable only if the coefficients of variation (CV) were <5%. Intra-assay CV were < 5% (2.5%), and
the inter-assay CV was <5% (4.2%).
Baseline fasting plasma C-peptide levels of all participants were within the expected range of fasting Cpeptide concentrations for normal individuals (shown as grey shaded area in Fig. 11a) (Endocrine
Sciences Inc.). Moreover, baseline levels of C-peptide were not significantly different between the IG
(red) and the DIG (blue) (p = 0.226) (Fig. 12a, Table 7).
In both groups over the 18 months of the study, we observed an increase in C-peptide levels. After the
first 9 months of the study, C-peptide levels were significantly increased relative to baseline regardless
of whether patients received the intervention or not (control period) (p < 0.001). This increase resulted
in C-peptide levels exceeding normal levels (Fig. 12a). During the next 9 months there was a significant
increase in C-peptide levels relative to levels at Time 1 in the DIG even after 9 months of intervention
(p = 0.022). Moreover there was a significant increase in C-peptide levels by 18 months in the IG
relative to levels at 9 months (p = 0.008).
C-peptide levels were 3.1 fold higher than the higher end of normal levels (2.1 ng/mL) in the delayed
intervention group and 2.8 fold higher than normal values in the intervention group at the end of the
study.

C-Peptide Levels at Each Time Point DIG vs IG
C-Peptide Concentration (ng/mL)

9
8
7
6
5
4
3
2

DIG
IG
Normal

0.4-2.1ng/mL

1

0
1

2

3

Figure 12a: Mean fasting plasma C-peptide concentration at each time point in the DIG (blue) vs the IG (red).
The grey shaded area represents the normative range37
for fasting plasma C-peptide concentrations in healthy
adults (Endocrine Sciences Inc.). The blue dashed line indicates the 9 month control period in the DIG.. Values
are represented as mean ± SEM. *P ≤ 0.05 **P ≤ 0.001. DIG (n)= 10, IG (n)= 12.

Table 7: Mean fasting plasma C-Peptide concentration at each time point in the DIG (blue) vs the IG (red) and P Values after 2way ANOVA analyses. Values are represented as mean ± SEM.
Mean Fasting Plasma C-peptide

Mean Difference in C-peptide

P Value (2 Way Repeated Measures

Concentration

Levels Between Time Points

ANOVA)

(ng/mL)
(ng/mL)

Time 0

IG

0.70 ± 0.47

Time 1

3.95 ± 0.39

Time 2

5.97 ± 1.01

Time 1 –

Time 2 –

Time 2 –

Time 0 vs

Time 1 vs

Time 2 vs

Time 0

Time 1

Time 0

Time 1

Time 2

Time 0

2.26 ± 0.89

6.03 ± 1.28

P<0.001

0.008

0.003

1.49 ± 0.82

5.69 ± 1.33

P<0.001

0.022

P<0.001

3.77 ±
0.38

DIG

P Value (2

0.87 ±

4.71 ±

0.17

0.49

0.226

0.131

6.41 ± 0.67

4.20 ±
0.52

0.361

Way
ANOVA) IG
vs DIG

To investigate the relative change in C-peptide levels within each group, we assessed the mean
differences in C-peptide levels between time points. During the 9 month control period in the DIG, Cpeptide levels increased by an average of 4.20 ± 0.52 ng/mL (Fig. 12b, Table 7). After a 9 month
intervention in the DIG, C-peptide levels increased by 1.49 ± 0.82 ng/mL (Fig. 12b, Table 7). This
increase was 2.81 fold lower than the increase seen in the control period in this group (p=0.022) and
therefore, there was a significantly reduced increase in C-peptide levels in this group, possibly as a
result of the intervention.
An average increase of 3.77 ± 0.38 ng/mL was observed in the IG during the first 9 months of their
intervention (Fig. 12b, Table 7). After an additional 9 months of intervention in the IG, C-peptide levels
increased by a further 2.26 ± 0.89 ng/mL (Fig. 12b, Table 7). Although, this increase was 1.7 fold lower
than the increase in C-peptide levels during the first 9 months of intervention in this group, indicating
that the additional enrichment continued to reduce the increase in C-peptide levels, it was not found to
be statistically significant (p>0.05).
C-peptide levels were shown to be increased by an average of 2.56 ± 0.47 ng/mL after one round of 9
months of intervention in both groups (Purple column of Fig. 12b).
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The increase in C-peptide levels after the first intervention in the IG was significantly higher than the
increase in C-peptide levels after the optimised intervention in the DIG (p=0.009), indicating that the
differences in the intervention received by the patients may have had an effect on C-peptide levels.

Differences in C-Peptide Levels Between
Timepoints
C-peptide Concentration (ng/mL)

*
*
*

*

5
4.5
4
3.5
3
2.5
2
1.5
1
0.5
0
Control
(DIG)

Intervention
(Group
(DIG) A)

Intervention
(Group
(IG) B)

Intervention
in
Intervention
Both
Groups
(DIG
+ IG)

Longitudinal
Intervention
(IG)

Figure 12b: The differences in C-peptide levels between time points was measured for each patient
and the mean of these differences is shown after a 9 month control period in the DIG (blue), 9
months of intervention in the IG (red) and the DIG (blue), after 9 months of intervention in both
groups was combined (purple) and after 18 months of longitudinal intervention in the IG relative to
measurements taken after IG. Values presented are mean ± SEM. *P < 0.05. DIG (n)= 10, IG (n)=
12.
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12.3. Salivary Cortisol Levels in Response to Environmental Enrichment:
Analysis of salivary cortisol was performed using a High Sensitivity Salivary Cortisol ELISA KIT 13002 (SALIMETRICS), the details of the method are described in section 8.3. Samples were run in
duplicate in the same assay. Intra-assay CV was 1.36%, and the inter-assay CV was 4.60%.
Salivary cortisol levels followed the typical diurnal secretion pattern (Fig. 13a and Fig. 13b) as seen in
the normal population. In both the DIG and IG, levels of cortisol increased with the progression of time
regardless of whether patients received the intervention or underwent a control period.

Cortisol Concentrations Over One Day in DIG

Cortisol Concentration (µg/dL)

0.6
0.5

Time 0

0.4

Time 1

0.3

Time 2
Normal

0.2
0.1
0

08:00
1

12:00
2

Hours

16:00
3

20:004

Figure 13a: Mean salivary cortisol levels of HD patients in DIG at 08:00, 12:00. 16:00 and 20:00h in DIG at Time 0
(baseline), Time 1 (after control period) and Time 2 (after intervention) vs expected levels in normal population (green).
Values are presented as mean ± SEM. *P ≤0.05 (n)= 12.

Cortisol Concentrations Over One Day in IG
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Figure 13b: Mean salivary cortisol levels of HD patients in IG at awakening, 12:00, 16:00 and 20:00h in IG at Time 0
(baseline), Time 1 (after intervention) and Time 2 (after longitudinal intervention) vs expected levels in normal population
(green). Values presented as mean ± SEM. *P ≤ 0.05 (n)= 9.
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In order to investigate net cortisol responses in patients, the sum of cortisol concentrations at each of the
four time points (08:00, 12:00, 16:00 and 20:00) was calculated for each group to obtain a single net
cortisol concentration for each group at each time point (Fig. 13c, Table 8).
At baseline, the sum of cortisol concentrations were not significantly different between groups (p>0.05)
and both were below the expected range for normal individuals (HS salivary kit manual) (Fig. 13c,
Table 8).
In the DIG, after the 9 month control period, cortisol levels increased by 70% to 0.81 ± 0.16µg/dL from
baseline (shown in dotted line in Fig. 13c), an increase that was statistically significant (p=0.007). By
contrast, after 9 months of intervention in this group, cortisol concentrations remained at the same level,
0.83 ± 0.10 µg/dL (p>0.05) (Fig. 13c, Table 8).
After the first round of 9 month intervention in the IG, cortisol levels increased relative to baseline by
32% to 0.71 ± 0.07 µg/dL, and this increase was statistically significant (p = 0.027). After an additional
9 months of intervention (longitudinal intervention) in this group, cortisol levels increased more steeply,
by 52% to 1.07 ± 0.12 µg/dL, and this rise was statistically significant (p = 0.030) (Fig. 13c, Table 8).
At 18 months, salivary cortisol levels were lower (p=0.065) in the DIG than in the IG and remained
within the normative range wheras the IG had levels above the normal range (Fig. 13c, Table 8).

Net Salivary Cortisol Levels at Each Time Point:
DIG vs IG
*
*

Salivary Cortisol Concentration (µg/dL)

1.2

*
DIG

1

IG
Normal

0.8

0.65 – 0.90 µg/dL

0.6
0.4
0.2
0
1
0 Months

2
9 Months

3
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Figure 13c: The mean sum of salivary cortisol levels of HD patients at 08:00 + 12:00 + 16:00 + 20:00h at 0 Months, 9
41 in the DIG (blue) and the IG (red). The blue dashed line
Months and 18 Months after the commencement of the study
indicates the 9 month control period in the DIG. Values are presented as mean ± SEM. *P ≤ 0.05. DIG (n)= 12, IG (n)= 8.

In order to further investigate changes in salivary cortisol concentrations after the control period,
intervention, or longitudinal intervention, the mean difference in the sum of salivary cortisol
concentrations was calculated and plotted in Fig. 13d.
After the 9 month control period in the DIG, salivary cortisol levels increased by 0.34 ± 0.11 µg/dL.
Conversely, after 9 months of intervention in this group, cortisol levels decreased by 0.076 ± 0.18 µg/dL
in this group, producing a significant difference between time points (p=0.024) (Fig. 13d, Table 8)
After the first round of 9 months of intervention in the IG, salivary cortisol levels increased by 0.12 ±
0.11 µg/dL. After the second round of intervention in this group, cortisol levels increased by a greater
amount, 0.24 ± 0.21 µg/dL, however there was no statistically significant difference between the
increases in cortisol between the two interventions in the IG (p>0.05). Salivary cortisol levels increased
by an average of 0.01 ± 0.11 µg/dL during one round of 9 months of intervention in both groups.
Increases in cortisol levels were significantly less after intervention relative to the control period by a
signifcantly lower extent in the combined intervention relative to the control period (p=0.023), (Fig 13d,
Table 8).

Difference in Net Cortisol Levels in DIG vs IG
*
*

Cortisol Concentration (µg/dL)

0.5
0.4
0.3
0.2
0.1
0
-0.1
-0.2
-0.3
Control (DIG)

Intervention (DIG)

Intervention (IG)

Intervention (DIG +
IG)

Longitudinal
Intervention (IG)

Figure 13d: The difference in the sum of salivary cortisol concentrations taken over a day for each patient was
calculated between each time point and the mean of these differences after a 9 month control period in the DIG
(blue), 9 months of intervention in IG (red) and the DIG (blue), after 9 months of intervention in both groups was
combined (purple) and after 18 months of longitudinal intervention in the IG were plotted above. Values are
presented as mean ± SEM. *P < 0.05. DIG (n) = 12, IG (n) = 8.
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Table 8: Mean salivary cortisol concentrations at each time point in the DIG (blue) vs the IG (red) and P Values after 2-way repeated
measures ANOVA analysis. Values are represented as mean ± SEM.

Mean Salivary Cortisol

Mean Difference in Salivary Cortisol

P Value (2 Way Repeated Measures

Concentration

Levels Between Time Points

ANOVA)

(μg/dL ± SEM)

(μg/dL ± SEM)

Time 0

IG

Time 1

Time 2

0.53 ± 0.06 0.71 ± 0.07 1.07 ± 0.12

Time 1 –

Time 2 –

Time 2 –

Time 0 vs

Time 1 vs

Time 2 vs

Time 0

Time 1

Time 0

Time 1

Time 2

Time 0

0.12 ±

0.24 ± 0.21

0.33 ± 0.09

0.090

0.013

-0.07 ± 0.18 0.28 ± 0.11

0.014

0.472

p<0.001

0.11

DIG

P Value

0.48 ±

0.81 ±

0.05

0.11

0.250

0.361

0.83 ± 0.10

0.34 ±

p<0.001

0.11

0.065

(2 Way
ANOVA)
IG vs
DIG

As levels of cortisol are the highest upon awakening, and changes in cortisol levels are able to be more
clearly distinguished at this time point, we aimed to investigate levels in the morning in patients at
different time points.
After the 9 month control period in the DIG, morning salivary cortisol levels increased by 0.19 ± 0.03
µg/dL, from baseline. Conversely, after the intervention in this group, morning cortisol levels decreased
by an average by 0.03 ± 0.07 µg/dL, rendering a significant difference in the change in levels between
time points (p=0.006) (Fig. 13e).
Following 9 months of intervention in the IG, morning cortisol levels increased by 0.144 ± 0.11 µg/dL.
After the longitudinal intervention in this group, cortisol concentrations increased by 0.046 ± 0.09
µg/dL (Fig. 13e). Although this increase was 3 fold lower than the increase seen during the first round of
intervention in this group, the differences in levels between the first and second rounds of intervention
were not found to be statistically significant (p>0.05) (Table 8).
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Salivary Cortisol Concentration (μg/dL)

Difference in Morning Cortisol Levels Over
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Figure 13e: The mean difference in morning salivary cortisol concentrations after a 9 month control period
in the DIG (blue), 9 months of intervention in IG (red) and the DIG (blue), after 9 months of intervention in
both groups was combined (purple) and after 18 months of longitudinal intervention in the IG. Values are
presented as mean ± SEM *P < 0.05. DIG (n) = 12, IG (n) = 8.

Differences in salivary cortisol concentrations at midday (12:00h), afternoon (16:00 h) and evening
(20:00h) were also analysed and although the results mimicked the pattern of change seen in morning
cortisol levels, no statistically significant differences were found between time points in the DIG and IG
(data not shown).
Summary of Results
Levels of C-peptide, a marker of metabolic processes in HD patients, increased throughout the study,
regardless of whether patients received the intervention or underwent a control period, however
increases in C-peptide appeared to be reduced by the intervention. Overall, C-peptide levels exceeded
levels seen in the normal population. Cortisol, a marker of HPA function in our patients, increased after
18 months of intervention, to levels higher than normal range however, levels seemed to stabilise within
the normal expected range after 9 months of optimised intervention in the DIG. BDNF, a marker of
neural function, continued to decrease in patients regardless of whether they underwent a control period
or 9 months of intervention, however after 18 months of intervention, levels were significantly increased
in patients. There was however, a clear gender difference in the BDNF response with significantly
increased BDNF levels observed only in females in response to 18 months of environmental
enrichment. Eighteen months of intervention was required for BDNF levels to stabilise in males.
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13. DISCUSSION
BDNF
Here for the first time, we document amelioration of BDNF deficits after longitudinal environmental
enrichment in HD patients. This result is in accordance with previous studies in mice which have
reported an association between environmental enrichment and the transcriptional upregulation of genes
encoding neurotrophins such as BDNF, essential for neurogenesis, learning and memory (Rampon et al.,
2000, Spires et al., 2004).
BDNF is the most abundant neurotrophin in the brain and is essential for neuronal survival. An enriched
environment is known to enhance learning and memory performance in WT rodents (normal)
(Nithianantharajah and Hannan, 2006), delay onset and cognitive decline in mouse models of HD (Pang
et al., 2006) and to promote structural and morphological changes together with upregulation of BDNF
expression in the brain in mouse models of HD (Spires et al., 2004, Falkenberg et al., 1992). Although
these studies have been conducted in mouse models, they are in accordance with our finding of
amelioration of BDNF deficits in HD patients after environmental enrichment treatment.
In this study we also demonstrate clear gender differences in the BDNF response to environmental
enrichment (Fig. 11c and Fig. 11d). After 18 months of intervention, BDNF levels increased
significantly in females and remained relatively stable in males (Fig. 11d). These findings are
synonymous with results from previous studies which have found that responses to environmental
enrichment exhibit differences with gender in mouse models of HD (Wood et al., 2010, Zajac et al.,
2010). Wood et al., reported improved overall cognitive performance in female HD mouse models in
comparison to male mice (2010) and increased handling of female HD mice has been reported to
beneficially affect cognitive performance while having a negative effect in male mice (Wood et al.,
2010). Additionally, Zajac and colleagues also demonstrated gender dependent BDNF changes in both
WT mice and mouse models of HD after environmental stimuli (2010), where amelioration of BDNF
deficits after wheel running were found only in female mice (Zajac et al., 2010). Similar gender-specific
effects of environmental enrichment on learning and memory have been shown in mouse models of
Down syndrome, where environmental enrichment had beneficial effects on spatial learning in female
mice but deleterious effects in male mice (Martinez-Cue et al., 2002). This suggests that female HD
patients may be more sensitive to the beneficial effects of environmental enrichment than males.
Interestingly, both genders required a longitudinal intervention of 18 months in order for improvements
to take effect. Nine months of intervention did not improve BDNF levels in either gender and this result
is in accordance with a previous report in which short term exercise did not induce any changes in
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BDNF mRNA levels (Berchtold et al., 2010). It could be postulated that an extended period of time is
required for environmental enrichment to have functional effects on HD patients.
Platelets acquire nervous system BDNF after crossing the blood brain barrier (Fujimura 2002). Hence
changes in BDNF production in the brain may be reflected in BDNF concentrations in the blood. BDNF
concentrations in our patients were lower than normal expected levels and this finding is in agreement
with previous studies (Zuccato et al., 2001, Cattaneo et al., 2005, Ciammola et al., 2007) which have
reported lowered BDNF levels in HD cells, animal models of HD and human brain tissue from HD
patients. This finding is to be expected as neuronal degeneration in human HD mainly affects the
striatum and cerebral cortex (Reiner et al., 1988, Rosas et al., 2008), regions where BDNF is most
abundant in humans (Altar et al., 1997).

The decrease in BDNF levels could be attributed to reduced gene expression of BDNF, caused by a loss
of WT HTT protein function and a gain of toxic function of the mutant HTT protein. WT HTT
stimulates BDNF gene transcription by acting at the level of the BDNF exon 2 promoter whereas the
presence of the pathological CAG expansion in HD abolishes the ability to sustain BDNF gene
transcription in HD (Zuccato et al., 2001). Overexpression of WT HTT has been reported to increase
BDNF production (Zuccato et al., 2001); And it has been found that BDNF exon 2 promoter is 60% less
active in cells over expressing mutant HTT than in parental cells (Zuccato et al., 2001). Reports have
found that the WT, but not the mutant, protein influences the activity of a repressor element 1/neuronrestrictive silencer factor (RE1/NRSE) within the BDNF exon 2 promoter (Zuccato et al., 2001). In
addition to decreased BDNF exon 2 promoter activity in HD, BDNF exon 3 and 4 have also been
indicated in HD and reduced BDNF mRNA 3 and 4 has been reported in animal models of HD (Hermel
et al., 2004).

In future studies it would be interesting to analyse if the impaired BDNF anterograde transport, which
has been extensively reported in HD, is influenced by environmental enrichment. This was not possible
by analysing peripheral levels of BDNF in our study, however previous studies in mouse models of HD
have found that environmental enrichment rescues striatal and hippocampal protein deficits whereas
antero-medial cortical levels of BDNF are unaffected (Spires et al., 2004). This could mean that
environmental enrichment rescues the impaired cortico-striatal transport of BDNF. MRI studies of
environmentally enriched HD patients are currently underway and will provide information on rescue of
grey matter which could contribute to rescue of BDNF levels. Furthermore, studies analysing post
mortem brain tissue in environmentally enriched HD patients compared to control HD patients mapping
the localisation of BDNF would be of interest.
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BDNF deficits contribute significantly to the pathogenesis of HD (Canals et al., 2004). Mouse models
of HD which were crossed with heterozygous BDNF knock-out mice showed an earlier onset of motor
dysfunction, reduction of stratal volume attributed to a loss of striatal neurons which suggests that it
may be a valuable candidate for therapeutic intervention in HD (Canals et al., 2004). Studies in which
BDNF has been delivered by lentiviral transfection to primary neurons expressing mutant HTT have
demonstrated that it protects against cell death induced by the mutant HTT (Canals et al., 2004). Despite
these promising results, exogenous BDNF supplementation raises a number of different problems, the
first of which is determining the amount of BDNF that is required to reach the affected neurons, which
is compounded by the fact that BDNF is relatively unstable and only a small amount is able to cross the
blood brain barrier (Knusel et al., 1992, Pardridge, 2002). If the amount of BDNF reaching the affected
neurons is too small it may not be sufficient to produce the required effects. In contrast if the amount is
too large, it may be deleterious as high BDNF levels have been shown to down regulate the expression
of the BDNF receptor, tyrosine-related kinase B receptor, thus reducing the signalling pathway activated
by BDNF and therefore blocking any beneficial effect (Frank et al., 1996, Knusel et al., 1997,
Sommerfeld et al., 2000). Moreover, excess BDNF has been reported to give rise to epileptic activity
(Binder et al., 2001). It could be because of these reasons that subcutaneous and intrathecal BDNF
administrations have met with little success (1999, Ochs et al., 2000). Environmental enrichment and
physical exercise, therapies which have been observed to enhance endogenous production of BDNF
have recently become of increased interest as they provide BDNF levels in normal physiological
quantities.

As BDNF is also produced by muscle cells during contraction (Pedersen et al., 2009), it could be argued
that our BDNF measurements do not reflect the in-brain concentration of this neurotrophic factor, and
that the exercise undertaken by our patients may have caused a transient increase in muscle- derived
BDNF. It has been reported however, that BDNF produced by muscle cells during contraction exerts its
actions locally and is not released into the circulation (Pedersen et al., 2009). In addition to expression
in skeletal muscle and CNS, BDNF has also been shown to be expressed in liver (Cassiman et al., 2001)
heart, lung (Timmusk et al., 1993), pancreas (Hanyu et al., 2003) and spleen (Laurenzi et al., 1994).
Because our ELISA kit detects all isoforms of BDNF, it could be suggested that the peripheral BDNF
changes observed in our patients’ whole blood were reflective of changes in BDNF expression from
sources other than brain tissue. However, a recent study has confirmed a positive correlation between
whole blood BDNF levels and hippocampal levels in rats (Klein et al., 2011). It would be useful to
investigate if this correlation is replicated in humans.
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Antidepressants, namely selective serotonin reuptake inhibitors (SSRIs), lithium, memantine, riluzole,
cystamine and cysteamine have all been reported to increase BDNF levels (Chuang, 2004). Because
depression is a common feature of HD, a number of patients who were involved in the study were
prescribed anti-depressants. Because all patients in the study remained on the same dosage of antidepressant medication throughout the study, anti-depressant use was not accounted for during analyses
of BDNF results.
Alcohol intake has also been reported to influence BDNF levels (McGough et al., 2004). Frequency and
amount of alcohol consumption was not recorded in our study, however in future studies, it would be
interesting to examine the effect of alcohol consumption on BDNF levels in HD patients.
Platelets are one of the major BDNF storage sites in the periphery in human beings (Fujimura et al.,
2002), however no association between BDNF and thrombocyte count has been reported (Trajkovska et
al., 2007) therefore platelet count was not measured in our patients. Aspirin treatment has been reported
to not affect platelet count (Erhart et al., 1999) furthermore, aspirin does not affect the release of BDNF
from platelets (Stoll et al., 2011). It is for these reasons that patients intake of aspirin was not accounted
for in BDNF analyses.
In order to further solidify our findings, it would be interesting to assess levels of BDNF after a period
of detraining in our patients.
It would be interesting to analyse other biochemical markers in the brain as markers of neurogenesis
including fibroblast growth factor (FGF). FGF is angiogenic, stimulates proliferation of astrocytes and
promotes survival and growth of neurons and has been reported to be increased by exercise
(Gospodarowicz et al., 1987). Moreover, epidermal growth factor (EGF) is important in promoting
survival and differentiation of post mitotic neurons and increases the density of newborn cells in the
subventricular zone. It would also be interesting to investigate glutamatergic activity which has been
reported to increase after exercise (Poon et al., 2006). Glutamate is involved in the mechanisms that
promote learning and memory and activation of glutamate receptors has a role in in the generation of
long term potentiation as a response to exercise (Holscher et al., 1999). Glutamate receptors, GluR1 and
GluR2, are related to long term potentiation mechanisms and undergo plastic changes after exercise in
healthy individuals (Dietrich et al., 2005, Real et al., 2010).
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C-peptide
Insulin levels continually increased throughout the 18 months of the study and exceeded normal
expected values (Fig. 12a). This result is in contrast to previous reports of impaired insulin secretion and
decreased insulin gene expression in mouse models of HD (Andreassen et al., 2002, Hurlbert et al.,
1999, Bjorkqvist et al., 2006). These studies were carried out in mouse models of HD which expressed a
highly expanded CAG repeat (145-150 CAG repeats), much longer than the average CAG repeat length
observed in our patients (43.4 CAG repeats). It is known that a correlation between CAG repeat and
glucose homeostasis exists, and glucose responsiveness decreasing with increased CAG repeat has been
reported (Josefsen et al., 2008). It would therefore be interesting to investigate if glucose homeostasis
abnormalities are observed in mouse models of HD expressing mutant HTT with a repeat length within
the range normally found in HD patients.
A study conducted in Serbia in 2008, (Lalic et al., 2008) reported impaired first phase insulin secretion
in HD patients. Comparisons of the characteristics of the group of patients in the study by Lalic and
colleagues (Lalic et al., 2008) with the patients in our study, reveals stark differences in the mean
disease duration between groups (7.1 years in the Lalic study versus 3.35 years in our study) which
suggests that impairments in insulin secretion may be evident with greater progression of disease.
Moreover, it is possible that the differences in the genetic background between the two groups could
contribute to the differences in insulin secretion.
Our results are also confounded by findings in earlier studies which have reported increased prevalence
of diabetes in HD patients, (Podolsky and Leopold, 1977, Farrer, 1985, Schubotz et al., 1976), none of
our patients were reported as diabetic. The difference in findings could be attributed to the fact that
these studies were all carried out before a genetic test for HD became available and the patients are
therefore not likely to be well characterised.
Insulin levels in our patients exceeded the normal expected range in both the DIG and IG, which may
indicate the presence of impaired insulin sensitivity. Decreased insulin sensitivity has been reported in
HD patients and mouse models of HD (Lalic et al., 2008, Bjorkqvist et al., 2006). Intranuclear
inclusions formed from aggregates of the mutant HTT protein have been found to be present in
pancreatic cells (Sathasivam et al., 1999, Andreassen et al., 2002). Therefore it is postulated that
intranuclear inclusions in pancreatic cells of HD patients may contribute to alterations in insulin
feedback mechanisms and impairments in beta cell function. Future tests that analyse insulin sensitivity
and beta cell function such as a homeostatic model assessment (HOMA) would be useful in helping to
determine if the elevated insulin levels observed in our patients are a result of impaired insulin
sensitivity.
49

A decrease in the elevation of insulin was seen after intervention compared to the control period in the
DIG, which may suggest that the enrichment program was partially alleviating the elevated levels of
insulin. Physical exercise has been widely reported to improve insulin sensitivity and improve glucose
homeostasis in healthy individuals (van der Heijden et al., 2009, Gordon et al., 2012, Maarbjerg et al.,
2011) and this slight decrease in elevation of insulin could be attributed to the enrichment undertaken by
the patients.
Finally, it could be speculated that a portion of the rise in C-peptide levels in our study could be a result
of the progression of the disease through time, as to the best of our knowledge this is the first
longitudinal study which has analysed C-peptide levels in HD patients. Future studies with a larger
sample size are warranted to confirm this hypothesis. From our results, it can be concluded that there is
a significant fluctuation in insulin levels over the 18 months of the study, and testing insulin sensitivity
of patients could be informative in future studies.
CORTISOL
Throughout the study, cortisol levels continued to increase in patients in the IG group and exceeded
normal expected levels. They also increased during the control period in the DIG (Fig. 13c). This
finding is in line with previous studies that have assessed cortisol levels in HD patients and have
reported elevated cortisol production rates (Heuser et al., 1991, Leblhuber, 1993, Aziz et al., 2009b).
This finding could indicate HPA axis dysfunction and suggests that a disturbed central glucocorticoid
feedback may be present in HD patients (Aziz et al., 2009b).
Intranuclear inclusions containing the mutant HTT protein are evident in HD and substantial
hypothalamic atrophy and cell loss have been reported in HD patients (Kassubek et al., 2005). The
reason why the hypothalamus is preferentially affected in HD is unknown, however it has been
postulated that it could be as a result of increased interaction of mutant HTT with huntingtin-associated
protein 1 (Hap1) which is more abundantly expressed in the hypothalamus than in other brain regions
(Sheng et al., 2006). This could be related to the dysfunction of the HPA axis as evidenced by the
finding of abnormal levels of cortisol in the IG and increasing levels during the control period in the
DIG (Fig. 13c).
Moreover, impaired glucocorticoid receptor function in the hypothalamus could underlie the elevated
cortisol levels in patients (Aziz et al., 2007). The negative feedback mechanism of cortisol production is
regulated by two receptor subtypes in the brain; High affinity mineralocorticoid receptors in the
hippocampus, which determine basal cortisol levels, and low affinity glucocorticoid receptors in the
hypothalamus, particularly in the paraventricular nucleus. Paraventricular nucleus pathology has been
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reported in HD and is likely to contribute to the altered HPA axis seen in our patients (Aziz et al., 2007,
Vogt and Vogt, 1952). Additionally, as with BDNF, the mutant HTT protein may contribute to
alterations in gene expression of cortisol, however this hasn’t been studied in HD yet. It would be useful
to employ a dexamethasone suppression test in order to more fully assess feedback mechanisms within
the HPA axis in HD patients.
An altered immune profile is evident in HD patients, and neuroinflammation in HD has been reported
(Moller, 2010, Crocker et al., 2006). Elevated levels of inflammatory mediators including IL-1b and
TNF-α have been detected in the cerebrospinal fluid and plasma of HD patients (Moller, 2010). Cortisol
is one of the most potent anti-inflammatory hormones in the body (Cupps and Fauci, 1982) therefore it
could be postulated that the elevated levels of cortisol observed in our patients are in response to the
elevated inflammatory mediators present in HD patients.
The anti-inflammatory effects of exercise have been widely reported and are dependent upon the
frequency and amount of exercise carried out (Gleeson et al., 2011). Cortisol levels stabilised after nine
months of optimised intervention in the DIG (Fig. 13c) which comprised of three-times-weekly
exercise. However cortisol levels did not stabilise after eighteen months of a sub-optimal intervention in
the IG. Therefore it is possible that neuroinflammation in HD patients is partly alleviated by the
optimised intervention, which in turn leads to alleviation in cortisol levels. However this remains
speculative at this stage and may be worthy of investigation in future studies.
The optimised intervention undertaken by the DIG for nine months was comprised of 3-times-weekly
supervised intervention. Increased social interaction has been reported to ameliorate depressive
symptoms (Drevets, 2001) and to reduce cortisol levels (Uvnas-Moberg, 1998). Therefore it is
suggested that the social stimulation associated with the supervised intervention contributed to the
alleviation of cortisol levels during the 9-18 month period in this group.
It must be noted that medication records of patients indicated that no patients were prescribed
glucocorticoid medication such as prednisone and prednisolone. Androgens and phenytoin have been
reported to decrease cortisol measurements (Abraham et al., 1976), however, none of our patients were
on these medications.
Analysis of results from quality of life questionnaires filled out by the patients is currently underway
and therefore cannot be commented on. It would be interesting to determine if a correlation exists
between patients’ cortisol measurements and their perception of quality of life.
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Even mildly elevated cortisol levels have been associated with a number of clinically significant health
effects such as cognitive dysfunction (Lupien et al., 1998), plasma lipid disturbances, low bone density
(Raff et al., 1999), and increased morbidity related to cardiovascular disease (Otte et al., 2004), insulin
resistance and major depression (Brown et al., 2004). HD patients exhibit a number of symptoms and
signs that could be partly attributed to hypercortisolism such as memory deficits, mood disturbances,
skeletal muscle atrophy, impaired glucose tolerance, and decreased hippocampal volume. The
speculated impairment in insulin sensitivity observed in our patients in this study could partly be
attributed to elevated cortisol levels in our patients. Larger scale studies however, are needed to confirm
an association between high cortisol levels and clinical phenotype in HD patients. These findings are of
importance as anti-glucocorticoid therapy is presented as a therapeutic potential for HD patients and
environmental enrichment has been demonstrated as being a potential therapy of alleviating
hypercortisolism in HD patients.

13.1 LIMITATIONS
Due to the low prevalence rate of HD, our sample size is small (n=20) and this presented as the biggest
limitation as it decreased the statistical sensitivity of our study. In order to minimise this limitation,
appropriate stringent statistical analyses were conducted, such as a two way ANOVA to assess the
significance of our results. Although we observed substantial changes in biochemical markers between
time points, in some cases, they were considered statistically insignificant. We predict that with a larger
sample size statistical significance will be attained. Although it could be speculated that patient
compliance was a limiting factor in our study, we had greater than 80% compliance for all aspects of the
study.
14.

CONCLUSIONS

HD is a devastating disease and current pharmacological therapies do nothing to delay onset but act to
alleviate symptoms in patients. Environmental enrichment has been shown to be successful in delaying
onset and progression in several neurodegenerative diseases including Parkinson’s and Alzheimer’s
disease, and short trials have shown promising results in HD patients. In this study we proposed to study
the effects of an extended trial of environmental enrichment intervention on physiological processes by
analysing biochemical markers indicative of neural, metabolic and neuroendocrine pathways. We
showed that environmental enrichment produced positive benefits even with a small sample size. The
results from this preliminary study will inform the scientific community of the positive effects of
environmental enrichment on HD patients, in order for studies with a larger sample size to take place in
the hope that environmental enrichment will be integrated into current HD therapies.
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